<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetes Obes Metab</journal-id><journal-id journal-id-type="iso-abbrev">Diabetes Obes Metab</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1463-1326</journal-id><journal-id journal-id-type="publisher-id">DOM</journal-id><journal-title-group><journal-title>Diabetes, Obesity &#x00026; Metabolism</journal-title></journal-title-group><issn pub-type="ppub">1462-8902</issn><issn pub-type="epub">1463-1326</issn><publisher><publisher-name>Blackwell Publishing Ltd</publisher-name><publisher-loc>Oxford, UK</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26179187</article-id><article-id pub-id-type="pmc">5042083</article-id><article-id pub-id-type="doi">10.1111/dom.12534</article-id><article-id pub-id-type="publisher-id">DOM12534</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Once&#x02010;weekly glucagon&#x02010;like peptide&#x02010;1 receptor agonist dulaglutide is non&#x02010;inferior to once&#x02010;daily liraglutide and superior to placebo in <styled-content style="fixed-case">J</styled-content>apanese patients with type 2 diabetes: a 26&#x02010;week randomized phase <styled-content style="fixed-case">III</styled-content> study</article-title><alt-title alt-title-type="left-running-head">Miyagawa et al</alt-title></title-group><contrib-group><contrib id="dom12534-cr-0001" contrib-type="author"><name><surname>Miyagawa</surname><given-names>J.</given-names></name><xref ref-type="aff" rid="dom12534-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="dom12534-cr-0002" contrib-type="author"><name><surname>Odawara</surname><given-names>M.</given-names></name><xref ref-type="aff" rid="dom12534-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="dom12534-cr-0003" contrib-type="author"><name><surname>Takamura</surname><given-names>T.</given-names></name><xref ref-type="aff" rid="dom12534-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="dom12534-cr-0004" contrib-type="author" corresp="yes"><name><surname>Iwamoto</surname><given-names>N.</given-names></name><xref ref-type="aff" rid="dom12534-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="dom12534-cr-0005" contrib-type="author"><name><surname>Takita</surname><given-names>Y.</given-names></name><xref ref-type="aff" rid="dom12534-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="dom12534-cr-0006" contrib-type="author"><name><surname>Imaoka</surname><given-names>T.</given-names></name><xref ref-type="aff" rid="dom12534-aff-0004">
<sup>4</sup>
</xref></contrib></contrib-group><aff id="dom12534-aff-0001"><label><sup>1</sup></label><named-content content-type="organisation-division">Division of Diabetes, Endocrinology and Metabolism, Department of Internal Medicine</named-content><institution>Hyogo College of Medicine</institution><named-content content-type="city">Nishinomiya</named-content><country country="JP">Japan</country></aff><aff id="dom12534-aff-0002"><label><sup>2</sup></label><named-content content-type="organisation-division">Division of Diabetes, Endocrinology and Metabolism, Department of Diabetes, Endocrinology, Metabolism and Rheumatology</named-content><institution>Tokyo Medical University</institution><named-content content-type="city">Tokyo</named-content><country country="JP">Japan</country></aff><aff id="dom12534-aff-0003"><label><sup>3</sup></label><named-content content-type="organisation-division">Department of Comprehensive Metabology</named-content><institution>Kanazawa University Graduate School of Medical Sciences</institution><named-content content-type="city">Kanazawa</named-content><country country="JP">Japan</country></aff><aff id="dom12534-aff-0004"><label><sup>4</sup></label><institution>Eli Lilly Japan K.K</institution><named-content content-type="city">Kobe</named-content><country country="JP">Japan</country></aff><author-notes><corresp id="correspondenceTo"><label>*</label><italic>Correspondence to</italic>: Dr Noriyuki Iwamoto, Eli Lilly Japan K.K., 7&#x02010;1&#x02010;5, Isogamidori, Chuoku, Kobe 6510086, Japan.<break/>
E&#x02010;mail: <email>Iwamoto_noriyuki@lilly.com</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>20</day><month>8</month><year>2015</year></pub-date><pub-date pub-type="ppub"><month>10</month><year>2015</year></pub-date><volume>17</volume><issue>10</issue><issue-id pub-id-type="doi">10.1111/dom.2015.17.issue-10</issue-id><fpage>974</fpage><lpage>983</lpage><history><date date-type="received"><day>06</day><month>4</month><year>2015</year></date><date date-type="rev-recd"><day>22</day><month>6</month><year>2015</year></date><date date-type="accepted"><day>02</day><month>7</month><year>2015</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2015 John Wiley & Sons Ltd <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2015 The Authors. Diabetes, Obesity and Metabolism published by John Wiley &#x00026; Sons Ltd.</copyright-statement><license license-type="creativeCommonsBy-nc"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">Creative Commons Attribution&#x02010;NonCommercial</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:DOM-17-974.pdf"/><abstract id="dom12534-abs-0001"><sec id="dom12534-sec-0001"><title>Aims</title><p id="dom12534-para-0001">To examine the efficacy and safety of once&#x02010;weekly dulaglutide monotherapy (0.75&#x02009;mg) compared with placebo and once&#x02010;daily liraglutide (0.9&#x02009;mg) in <styled-content style="fixed-case">J</styled-content>apanese patients with type 2 diabetes.</p></sec><sec id="dom12534-sec-0002"><title>Methods</title><p id="dom12534-para-0002">This was a phase <styled-content style="fixed-case">III</styled-content>, 52&#x02010;week (26&#x02010;week primary endpoint), randomized, double&#x02010;blind, placebo&#x02010;controlled, open&#x02010;label comparator (liraglutide) trial comparing 492 <styled-content style="fixed-case">J</styled-content>apanese patients with type 2 diabetes (dulaglutide, n&#x02009;=&#x02009;281; liraglutide, n&#x02009;=&#x02009;141; and placebo, n&#x02009;=&#x02009;70) who were aged &#x02265;20&#x02009;years. Patients and investigators were blinded to treatment assignment for dulaglutide and placebo but not for liraglutide. The primary objective evaluated the superiority of dulaglutide versus placebo on change from baseline in glycated haemoglobin (<styled-content style="fixed-case">HbA1c</styled-content>) at 26&#x02009;weeks. Analyses were performed on the full analysis set.</p></sec><sec id="dom12534-sec-0003"><title>Results</title><p id="dom12534-para-0003">At 26&#x02009;weeks, once&#x02010;weekly dulaglutide was superior to placebo and non&#x02010;inferior to once&#x02010;daily liraglutide for <styled-content style="fixed-case">HbA1c</styled-content> change from baseline [least squares mean difference: dulaglutide vs placebo &#x02212;1.57% (95% confidence interval &#x02212;1.79 to &#x02212;1.35); dulaglutide vs liraglutide &#x02212;0.10% (95% confidence interval &#x02212;0.27 to 0.07)]. The most frequently reported adverse events were nasopharyngitis, constipation, diarrhoea, nausea, abdominal distension and decreased appetite; only decreased appetite was different between the dulaglutide and liraglutide groups [dulaglutide, n&#x02009;=&#x02009;2 (0.7%); liraglutide, n&#x02009;=&#x02009;8 (5.8%); p&#x02009;=&#x02009;0.003]. Nine (1.8%) patients experienced hypoglycaemia [dulaglutide, n&#x02009;=&#x02009;6 (2.1%); liraglutide, n&#x02009;=&#x02009;2 (1.5%); placebo, n&#x02009;=&#x02009;1 (1.4%)], with no event being severe.</p></sec><sec id="dom12534-sec-0004"><title>Conclusions</title><p id="dom12534-para-0004">In <styled-content style="fixed-case">J</styled-content>apanese patients with type 2 diabetes, once&#x02010;weekly dulaglutide (0.75&#x02009;mg) was superior to placebo and non&#x02010;inferior to once&#x02010;daily liraglutide (0.9&#x02009;mg) for reduction in <styled-content style="fixed-case">HbA1c</styled-content> at 26&#x02009;weeks. Dulaglutide was safe and well tolerated.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="dom12534-kwd-0001">dulaglutide</kwd><kwd id="dom12534-kwd-0002"><styled-content style="fixed-case">GLP</styled-content>&#x02010;1 receptor agonist</kwd><kwd id="dom12534-kwd-0003">liraglutide</kwd><kwd id="dom12534-kwd-0004">placebo</kwd><kwd id="dom12534-kwd-0005">type 2 diabetes</kwd></kwd-group><funding-group><award-group><funding-source>Boehringer Ingelheim</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Eli Lilly and Company</funding-source></award-group></funding-group><funding-group><award-group><funding-source>AstraZeneca</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Daiichi Sankyo</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Kowa Pharmaceutical</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Novartis Pharma</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Ono Pharmaceutical</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Sanwa Kagaku Kenkyusho</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Sanofi</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Novo Nordisk</funding-source></award-group></funding-group><counts><page-count count="10"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>dom12534</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>October 2015</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:4.9.4 mode:remove_FC converted:29.09.2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="dom12534-sec-0005"><title>Introduction</title><p id="dom12534-para-0005">Glucagon&#x02010;like peptide&#x02010;1 (GLP&#x02010;1) is a member of an endogenous class of incretin hormones synthesized in intestinal epithelial L&#x02010;cells as a response to gastrointestinal nutrients <xref rid="dom12534-bib-0001" ref-type="ref">1</xref>. GLP&#x02010;1 enhances glucose&#x02010;dependent secretion of insulin <xref rid="dom12534-bib-0002" ref-type="ref">2</xref>, <xref rid="dom12534-bib-0003" ref-type="ref">3</xref>, inhibits glucagon secretion <xref rid="dom12534-bib-0004" ref-type="ref">4</xref>, slows gastric emptying <xref rid="dom12534-bib-0005" ref-type="ref">5</xref> and reduces food intake <xref rid="dom12534-bib-0006" ref-type="ref">6</xref>, <xref rid="dom12534-bib-0007" ref-type="ref">7</xref>.</p><p id="dom12534-para-0006">Dulaglutide (Eli Lilly and Co., Indianapolis, IN, USA), a long&#x02010;acting GLP&#x02010;1 receptor agonist <xref rid="dom12534-bib-0008" ref-type="ref">8</xref>, mimics some endogenous GLP&#x02010;1 effects. Dulaglutide has been approved in the USA and European Union at once&#x02010;weekly doses of 0.75 and 1.5&#x02009;mg as a subcutaneous injection to improve glycaemic control in patients with type 2 diabetes <xref rid="dom12534-bib-0009" ref-type="ref">9</xref>, <xref rid="dom12534-bib-0010" ref-type="ref">10</xref>, and has been approved in Japan at a once&#x02010;weekly dose of 0.75&#x02009;mg to improve glycaemic control in patients with type 2 diabetes.</p><p id="dom12534-para-0007">Dulaglutide has been modified to stabilize against dipeptidyl peptidase&#x02010;4 inactivation, increase the solubility of the peptide, reduce immunogenic potential and increase its activity duration. The pharmacokinetic half&#x02010;life of dulaglutide in Japanese patients is approximately 5&#x02009;days, supporting once&#x02010;weekly dosing.</p><p id="dom12534-para-0008">In global clinical trials completed to date, dulaglutide (1.5&#x02009;mg) has been shown to be superior to metformin, sitagliptin and exenatide twice daily and non&#x02010;inferiority to liraglutide (1.8&#x02009;mg) for glycated haemoglobin (HbA1c) changes, and has been associated with reductions in body weight in patients with type 2 diabetes <xref rid="dom12534-bib-0011" ref-type="ref">11</xref>, <xref rid="dom12534-bib-0012" ref-type="ref">12</xref>, <xref rid="dom12534-bib-0013" ref-type="ref">13</xref>, <xref rid="dom12534-bib-0014" ref-type="ref">14</xref>.</p><p id="dom12534-para-0009">In the present study, we compared once&#x02010;weekly dulaglutide (0.75&#x02009;mg) with placebo and once&#x02010;daily liraglutide (0.9&#x02009;mg, the highest available dose in Japan), with regard to multiple efficacy and safety markers. The results from the present study were used to evaluate dulaglutide as a treatment for Type 2 diabetes in Japanese patients, and this study was the first comparison of a once&#x02010;weekly GLP&#x02010;1 receptor agonist with once&#x02010;daily liraglutide in Japanese patients.</p></sec><sec id="dom12534-sec-0006"><title>Materials and Methods</title><sec id="dom12534-sec-0007"><title>Study Design and Participants</title><p id="dom12534-para-0010">This study was a 52&#x02010;week, multicentre, randomized, placebo&#x02010;controlled, double&#x02010;blind (dulaglutide and placebo) and open&#x02010;label liraglutide comparator trial examining the efficacy and safety of once&#x02010;weekly dulaglutide monotherapy in Japanese patients with type 2 diabetes who were discontinued from their oral antidiabetic medication (OAM) monotherapy or were OAM&#x02010;na&#x000ef;ve. These analyses present the data from this study through the 26&#x02010;week primary endpoint. These data were collected at 33 Japanese sites between April 2012 and October 2013. The study was registered with <ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</ext-link> (NCT01558271).</p><p id="dom12534-para-0011">During the 2&#x02010;week screening period, patients were screened for eligibility and then entered a 2&#x02010;week lead&#x02010;in period for OAM&#x02010;na&#x000ef;ve patients or an 8&#x02010;week wash&#x02010;out period for patients receiving OAM monotherapy.</p><p id="dom12534-para-0012">Eligible Japanese subjects were male or female, aged &#x02265;20&#x02009;years, were OAM&#x02010;na&#x000ef;ve (diet and exercise only) or had discontinued OAM monotherapy (excluding thiazolidinedione). Eligible patients had a body mass index (BMI) in the range of 18.5&#x02013;35.0&#x02009;kg/m<sup>2</sup> and a confirmed HbA1c value at the randomization visit of 7.0&#x02013;10.0%.The key exclusion criteria for patients screened were: type 1 diabetes, previous GLP&#x02010;1 receptor agonist treatment, treatment with more than half of the sulphonylurea maximum dose at screening, current insulin or thiazolidinedione use, chronic systemic glucocorticoid use, or gastric emptying abnormality. Eligible patients were randomized and treated during the 26&#x02010;week primary evaluation period. At 26&#x02009;weeks, patients in the placebo group were switched to once&#x02010;weekly dulaglutide for the remainder of the 52&#x02010;week controlled study. At the completion of participation or early discontinuation, all patients were required to participate in a 30&#x02010;day safety follow&#x02010;up period.</p><p id="dom12534-para-0013">A common protocol was approved at each site by the relevant institutional review board, and the study was performed in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice <xref rid="dom12534-bib-0015" ref-type="ref">15</xref>. Each patient provided written informed consent before participation.</p></sec><sec id="dom12534-sec-0008"><title>Procedures</title><p id="dom12534-para-0014">Eligible patients were randomized to treatment at a 4&#x02009;:&#x02009;2&#x02009;:&#x02009;1 ratio (dulaglutide: liraglutide: placebo). Randomization was stratified by pre&#x02010;study OAM status (yes/no), BMI group (&#x0003c;25 and &#x02265;25&#x02009;kg/m<sup>2</sup>), and HbA1c (&#x02264;8.5 or &#x0003e;8.5%). The randomization was carried out according to a computer&#x02010;generated random sequence with an interactive voice response system. Patients and investigators were masked to dulaglutide and placebo treatment assignments but were not masked to liraglutide treatment assignment.</p><p id="dom12534-para-0015">Dulaglutide and placebo were provided as non&#x02010;identifiable solutions in prefilled syringes. Liraglutide was supplied as an open&#x02010;label pen. Subcutaneous blinded dulaglutide (or placebo) injections were initiated at the full dose. Subcutaneous liraglutide injections were uptitrated from 0.3&#x02009;mg/day during week 1 to 0.6&#x02009;mg/day during week 2 and 0.9&#x02009;mg/day starting at week 3, according to the Japanese label. Patients not tolerating study treatment were discontinued from the study drug but remained in the study to collect safety data.</p><p id="dom12534-para-0016">Hypoglycaemia was defined as a blood glucose concentration &#x02264;3.9&#x02009;mmol/l. Severe hypoglycaemia was defined as an episode that required the assistance of another person to actively administer carbohydrate, glucagon or other resuscitative actions. Patients were allowed to initiate rescue therapy for severe, persistent hyperglycaemia according to predefined thresholds on fasting blood glucose for at least 2&#x02009;weeks with no readily identifiable cause.</p><p id="dom12534-para-0017">Deaths, cardiovascular adverse events and pancreatitis were adjudicated by separate independent, external committees, using prespecified criteria, study evidence and clinical knowledge and experience. All patients were tested for the development of dulaglutide antidrug antibodies.</p></sec><sec id="dom12534-sec-0009"><title>Outcomes and Statistical Analyses</title><p id="dom12534-para-0018">The primary objective was to show the superiority of dulaglutide vs placebo as measured by HbA1c change from baseline at 26&#x02009;weeks. Key secondary objectives at 26&#x02009;weeks were to show that dulaglutide was non&#x02010;inferior or superior to liraglutide on HbA1c change from baseline values using a serial gatekeeping strategy <xref rid="dom12534-bib-0016" ref-type="ref">16</xref>. Secondary objectives at 26&#x02009;weeks evaluated the proportions of patients who achieved HbA1c targets (&#x0003c;7.0 or &#x02264;6.5%), change in fasting serum glucose from baseline, change in seven&#x02010;point self&#x02010;monitored blood glucose (SMBG) profiles from baseline, and change in body weight from baseline. SMBG profiles were collected on two separate, non&#x02010;consecutive days within 2&#x02009;weeks before baseline and weeks 14 and 26. Safety assessments included adverse events, vital signs (pulse rate and blood pressure), ECGs, laboratory variables and dulaglutide antidrug antibodies.</p><p id="dom12534-para-0019">The sample size of at least 490 randomized patients was selected to provide &#x0003e;99% power to demonstrate superiority of dulaglutide to placebo. This assumed a true mean difference in HbA1c change from baseline between dulaglutide and placebo of 0.8%, a common standard deviation of 1.1%, a one&#x02010;sided significance level of 0.025, and a 9% drop&#x02010;out rate between randomization and week 26. Moreover, assuming no difference between dulaglutide and liraglutide, the given sample size provided at least 90% power to confirm non&#x02010;inferiority of dulaglutide to liraglutide with a margin of 0.4%.</p><p id="dom12534-para-0020">Efficacy analyses used the full analysis set, defined as all randomized patients who took at least one dose of study drug. Safety analyses were conducted on the as&#x02010;treated population according to the patients' actual treatments (safety analysis set).</p><p id="dom12534-para-0021">The primary efficacy analysis model was a mixed model for repeated measures for change from baseline to week 26 for HbA1c. The model included treatment, prestudy therapy (OAM: yes/no), baseline BMI (&#x0003c;25/&#x02265;25&#x02009;kg/m<sup>2</sup>), visit, treatment by visit interaction as fixed effects, baseline HbA1c as a covariate, and patient as a random effect. An unstructured covariance structure was used to model the within&#x02010;patient errors. The 95% confidence interval (CI) for the treatment difference (dulaglutide&#x02009;&#x02212;&#x02009;placebo) in the least&#x02010;squares (LS) mean at week 26 based on this model was used to assess the primary objective. If the primary objective was met, the key secondary hypotheses for non&#x02010;inferiority and superiority of dulaglutide compared with liraglutide were to be tested using a serial gatekeeping strategy to control the family&#x02010;wise type I error rate. Statistical analyses comparing liraglutide and placebo were not conducted.</p><p id="dom12534-para-0022">For other continuous measurements, mixed model for repeated measures was performed with the same model as the primary efficacy analysis, with the relevant baseline value as a covariate. Seven&#x02010;point SMBG was analysed using an analysis of covariance model with terms for treatment, prestudy therapy and baseline BMI as fixed effects, and baseline value as a covariate.</p><p id="dom12534-para-0023">For categorical measurements, the Cochran&#x02013;Mantel&#x02013;Haenszel test stratified by prestudy therapy and baseline BMI or Fisher's exact test was performed.</p></sec></sec><sec id="dom12534-sec-0010"><title>Results</title><sec id="dom12534-sec-0011"><title>Patients</title><p id="dom12534-para-0024">Overall, 587 patients entered the study, 492 were randomized, 487 were treated with study drug, and 462 completed 26&#x02009;weeks of treatment (Figure <xref rid="dom12534-fig-0001" ref-type="fig">1</xref>). Thirty patients discontinued the study [dulaglutide, n&#x02009;=&#x02009;10 (3.6%); liraglutide, n&#x02009;=&#x02009;13 (9.2%); and placebo, n&#x02009;=&#x02009;7 (10.0%); p&#x02009;=&#x02009;0.020], with &#x02018;withdrawal by subject&#x02019; being the most common reason [dulaglutide, n&#x02009;=&#x02009;6 (2.1%); liraglutide, n&#x02009;=&#x02009;11 (7.8%); and placebo, n&#x02009;=&#x02009;5 (7.1%); p&#x02009;=&#x02009;0.011]. Patient demographics and baseline characteristics were similar between the groups (Table <xref rid="dom12534-tbl-0001" ref-type="table-wrap">1</xref>).</p><fig fig-type="Figure" xml:lang="en" id="dom12534-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Trial profile. Patients were randomized to treatment at a 4&#x02009;:&#x02009;2&#x02009;:&#x02009;1 ratio (dulaglutide: liraglutide: placebo). N&#x02009;=&#x02009;number of patients.</p></caption><graphic id="nlm-graphic-1" xlink:href="DOM-17-974-g001"><alt-text>DOM-12534-FIG-0001-b</alt-text></graphic></fig><table-wrap id="dom12534-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Baseline demographics and characteristics</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th id="dom12534-ent-0001" align="left" valign="bottom" rowspan="1" colspan="1">Variable</th><th align="left" id="dom12534-ent-0002" valign="bottom" rowspan="1" colspan="1">Dulaglutide 0.75&#x02009;mg (N&#x02009;=&#x02009;280)</th><th align="left" id="dom12534-ent-0003" valign="bottom" rowspan="1" colspan="1">Liraglutide 0.9&#x02009;mg (N&#x02009;=&#x02009;137)</th><th align="left" id="dom12534-ent-0004" valign="bottom" rowspan="1" colspan="1">Placebo (N&#x02009;=&#x02009;70)</th><th align="left" id="dom12534-ent-0005" valign="bottom" rowspan="1" colspan="1">Total (N&#x02009;=&#x02009;487)</th></tr></thead><tbody valign="top"><tr><td colspan="5" align="left" id="dom12534-ent-0006" valign="top" rowspan="1">Sex, n (%)</td></tr><tr><td style="padding-left:10%" id="dom12534-ent-0007" align="left" valign="top" rowspan="1" colspan="1">Men</td><td id="dom12534-ent-0008" align="left" valign="top" rowspan="1" colspan="1">228 (81)</td><td id="dom12534-ent-0009" align="left" valign="top" rowspan="1" colspan="1">113 (83)</td><td id="dom12534-ent-0010" align="left" valign="top" rowspan="1" colspan="1">55 (79)</td><td id="dom12534-ent-0011" align="left" valign="top" rowspan="1" colspan="1">396 (81)</td></tr><tr><td style="padding-left:10%" id="dom12534-ent-0012" align="left" valign="top" rowspan="1" colspan="1">Women</td><td id="dom12534-ent-0013" align="left" valign="top" rowspan="1" colspan="1">52 (19)</td><td id="dom12534-ent-0014" align="left" valign="top" rowspan="1" colspan="1">24 (18)</td><td id="dom12534-ent-0015" align="left" valign="top" rowspan="1" colspan="1">15 (21)</td><td id="dom12534-ent-0016" align="left" valign="top" rowspan="1" colspan="1">91 (19)</td></tr><tr><td id="dom12534-ent-0017" align="left" valign="top" rowspan="1" colspan="1">Mean (s.d.) age, years</td><td id="dom12534-ent-0018" align="left" valign="top" rowspan="1" colspan="1">57.2 (9.6)</td><td id="dom12534-ent-0019" align="left" valign="top" rowspan="1" colspan="1">57.9 (10.4)</td><td id="dom12534-ent-0020" align="left" valign="top" rowspan="1" colspan="1">57.7 (8.3)</td><td id="dom12534-ent-0021" align="left" valign="top" rowspan="1" colspan="1">57.4 (9.6)</td></tr><tr><td id="dom12534-ent-0022" align="left" valign="top" rowspan="1" colspan="1">Age &#x02265;65&#x02009;years, n (%)</td><td id="dom12534-ent-0023" align="left" valign="top" rowspan="1" colspan="1">68 (24)</td><td id="dom12534-ent-0024" align="left" valign="top" rowspan="1" colspan="1">39 (29)</td><td id="dom12534-ent-0025" align="left" valign="top" rowspan="1" colspan="1">13 (19)</td><td id="dom12534-ent-0026" align="left" valign="top" rowspan="1" colspan="1">120 (25)</td></tr><tr><td id="dom12534-ent-0027" align="left" valign="top" rowspan="1" colspan="1">Mean (s.d.) weight, kg</td><td id="dom12534-ent-0028" align="left" valign="top" rowspan="1" colspan="1">71.3 (12.5)</td><td id="dom12534-ent-0029" align="left" valign="top" rowspan="1" colspan="1">70.2 (12.5)</td><td id="dom12534-ent-0030" align="left" valign="top" rowspan="1" colspan="1">69.3 (11.6)</td><td id="dom12534-ent-0031" align="left" valign="top" rowspan="1" colspan="1">70.7 (12.4)</td></tr><tr><td id="dom12534-ent-0032" align="left" valign="top" rowspan="1" colspan="1">Mean (s.d.) BMI, kg/m<sup>2</sup>
</td><td id="dom12534-ent-0033" align="left" valign="top" rowspan="1" colspan="1">25.6 (3.6)</td><td id="dom12534-ent-0034" align="left" valign="top" rowspan="1" colspan="1">25.5 (3.5)</td><td id="dom12534-ent-0035" align="left" valign="top" rowspan="1" colspan="1">25.2 (3.2)</td><td id="dom12534-ent-0036" align="left" valign="top" rowspan="1" colspan="1">25.5 (3.5)</td></tr><tr><td id="dom12534-ent-0037" align="left" valign="top" rowspan="1" colspan="1">Mean (s.d.) diabetes duration, years</td><td id="dom12534-ent-0038" align="left" valign="top" rowspan="1" colspan="1">6.8 (5.6)</td><td id="dom12534-ent-0039" align="left" valign="top" rowspan="1" colspan="1">6.3 (6.0)</td><td id="dom12534-ent-0040" align="left" valign="top" rowspan="1" colspan="1">6.3 (5.1)</td><td id="dom12534-ent-0041" align="left" valign="top" rowspan="1" colspan="1">6.6 (5.6)</td></tr><tr><td id="dom12534-ent-0042" align="left" valign="top" rowspan="1" colspan="1">Mean (s.d.) HbA1c, %</td><td id="dom12534-ent-0043" align="left" valign="top" rowspan="1" colspan="1">8.15 (0.77)</td><td id="dom12534-ent-0044" align="left" valign="top" rowspan="1" colspan="1">8.08 (0.89)</td><td id="dom12534-ent-0045" align="left" valign="top" rowspan="1" colspan="1">8.20 (0.83)</td><td id="dom12534-ent-0046" align="left" valign="top" rowspan="1" colspan="1">8.14 (0.81)</td></tr><tr><td id="dom12534-ent-0047" align="left" valign="top" rowspan="1" colspan="1">HbA1c &#x0003e;8.5%, n (%)</td><td id="dom12534-ent-0048" align="left" valign="top" rowspan="1" colspan="1">89 (32)</td><td id="dom12534-ent-0049" align="left" valign="top" rowspan="1" colspan="1">42 (31)</td><td id="dom12534-ent-0050" align="left" valign="top" rowspan="1" colspan="1">26 (37)</td><td id="dom12534-ent-0051" align="left" valign="top" rowspan="1" colspan="1">157 (32)</td></tr><tr><td id="dom12534-ent-0052" align="left" valign="top" rowspan="1" colspan="1">Mean (s.d.) fasting serum glucose, mmol/l</td><td id="dom12534-ent-0053" align="left" valign="top" rowspan="1" colspan="1">9.4 (1.9)</td><td id="dom12534-ent-0054" align="left" valign="top" rowspan="1" colspan="1">9.0 (1.9)</td><td id="dom12534-ent-0055" align="left" valign="top" rowspan="1" colspan="1">9.6 (2.2)</td><td id="dom12534-ent-0056" align="left" valign="top" rowspan="1" colspan="1">9.3 (1.9)</td></tr><tr><td id="dom12534-ent-0057" align="left" valign="top" rowspan="1" colspan="1">Pre&#x02010;study OAM therapy, n (%)</td><td id="dom12534-ent-0058" align="left" valign="top" rowspan="1" colspan="1">94 (34)</td><td id="dom12534-ent-0059" align="left" valign="top" rowspan="1" colspan="1">48 (35)</td><td id="dom12534-ent-0060" align="left" valign="top" rowspan="1" colspan="1">22 (31)</td><td id="dom12534-ent-0061" align="left" valign="top" rowspan="1" colspan="1">164 (34)</td></tr><tr><td id="dom12534-ent-0062" align="left" valign="top" rowspan="1" colspan="1">OAM&#x02010;na&#x000ef;ve, n (%)</td><td id="dom12534-ent-0063" align="left" valign="top" rowspan="1" colspan="1">186 (66)</td><td id="dom12534-ent-0064" align="left" valign="top" rowspan="1" colspan="1">89 (65)</td><td id="dom12534-ent-0065" align="left" valign="top" rowspan="1" colspan="1">48 (69)</td><td id="dom12534-ent-0066" align="left" valign="top" rowspan="1" colspan="1">323 (66)</td></tr><tr><td id="dom12534-ent-0067" align="left" valign="top" rowspan="1" colspan="1">Mean (s.d.) HOMA2&#x02010;%&#x003b2; (fasting insulin)</td><td id="dom12534-ent-0068" align="left" valign="top" rowspan="1" colspan="1">34.5 (19.4)</td><td id="dom12534-ent-0069" align="left" valign="top" rowspan="1" colspan="1">36.9 (20.3)</td><td id="dom12534-ent-0070" align="left" valign="top" rowspan="1" colspan="1">33.0 (23.5)</td><td id="dom12534-ent-0071" align="left" valign="top" rowspan="1" colspan="1">34.9 (20.3)</td></tr><tr><td id="dom12534-ent-0072" align="left" valign="top" rowspan="1" colspan="1">Mean (s.d.) HOMA2&#x02010;%S (fasting insulin)</td><td id="dom12534-ent-0073" align="left" valign="top" rowspan="1" colspan="1">99.3 (53.8)</td><td id="dom12534-ent-0074" align="left" valign="top" rowspan="1" colspan="1">100.7 (52.8)</td><td id="dom12534-ent-0075" align="left" valign="top" rowspan="1" colspan="1">109.1 (57.8)</td><td id="dom12534-ent-0076" align="left" valign="top" rowspan="1" colspan="1">101.1 (54.1)</td></tr></tbody></table><table-wrap-foot><fn id="dom12534-note-0001"><p>All patients were from <styled-content style="fixed-case">J</styled-content>apan. <styled-content style="fixed-case">BMI</styled-content>, body mass index; <styled-content style="fixed-case">HbA1c</styled-content>, glycated haemoglobin; <styled-content style="fixed-case">HOMA2</styled-content>&#x02010;%&#x003b2;, updated homeostasis model assessment of &#x003b2;&#x02010;cell function; <styled-content style="fixed-case">HOMA2</styled-content>&#x02010;%<styled-content style="fixed-case">S</styled-content>, updated homeostasis model assessment of insulin sensitivity; <styled-content style="fixed-case">N</styled-content>, number of patients in full analysis set; <styled-content style="fixed-case">OAM</styled-content>, oral antihyperglycaemic medication; s.d., standard deviation.</p></fn></table-wrap-foot></table-wrap></sec><sec id="dom12534-sec-0012"><title>Efficacy</title><p id="dom12534-para-0025">At 26&#x02009;weeks, once&#x02010;weekly dulaglutide was superior to placebo for HbA1c change from baseline (p&#x02009;&#x0003c;&#x02009;0.001; Figures <xref rid="dom12534-fig-0002" ref-type="fig">2</xref>A, <xref rid="dom12534-fig-0003" ref-type="fig">3</xref>A). Dulaglutide was also non&#x02010;inferior, but not superior, to once&#x02010;daily liraglutide (p<sub>non&#x02010;inferiority</sub>&#x02009;&#x0003c;&#x02009;0.001). The LS mean (standard error) changes in HbA1c from baseline to 26&#x02009;weeks were &#x02212;1.43% (0.05) for dulaglutide, &#x02212;1.33% (0.07) for liraglutide, and 0.14% (0.10) for placebo. The LS mean difference between dulaglutide and placebo was &#x02212;1.57% (95% CI &#x02212;1.79, &#x02212;1.35) and between dulaglutide and liraglutide was &#x02212;0.10% (95% CI &#x02212;0.27, 0.07). For each timepoint from baseline to primary endpoint, dulaglutide significantly reduced HbA1c compared with placebo (p&#x02009;&#x0003c;&#x02009;0.001 all timepoints; Figure <xref rid="dom12534-fig-0002" ref-type="fig">2</xref>A).</p><fig fig-type="Figure" xml:lang="en" id="dom12534-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Glycated haemoglobin (<styled-content style="fixed-case">HbA1c</styled-content>), fasting serum glucose and body weight baseline values up to 26&#x02009;weeks. (A) <styled-content style="fixed-case">HbA1c</styled-content> values from baseline to 26&#x02009;weeks (%). (B) Fasting serum glucose values from baseline to 26&#x02009;weeks (mmol/l). (C) Body weight change from baseline to 26&#x02009;weeks. <styled-content style="fixed-case">FSG</styled-content>, fasting serum glucose; <styled-content style="fixed-case">LSM</styled-content>, least&#x02010;squares mean; s.e., standard error. *p&#x02009;&#x0003c;&#x02009;0.001 dulaglutide vs placebo. &#x000a7;All dulaglutide comparisons vs placebo and liraglutide p&#x02009;&#x0003e;&#x02009;0.05.</p></caption><graphic id="nlm-graphic-3" xlink:href="DOM-17-974-g002"><alt-text>DOM-12534-FIG-0002-c</alt-text></graphic></fig><fig fig-type="Figure" xml:lang="en" id="dom12534-fig-0003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Glycated haemoglobin (<styled-content style="fixed-case">HbA1c</styled-content>) change from baseline, <styled-content style="fixed-case">HbA1c</styled-content> target, fasting serum glucose, and self&#x02010;monitored blood glucose. (A) Change in <styled-content style="fixed-case">HbA1c</styled-content> from baseline at week 26 (%). (B) Proportions of patients achieving predefined <styled-content style="fixed-case">HbA1c</styled-content> targets at week 26 (<styled-content style="fixed-case">LOCF</styled-content>). (C) Change in fasting serum glucose from baseline at week 26 (mmol/l). (D) Seven&#x02010;point <styled-content style="fixed-case">SMBG</styled-content> measurements at baseline and endpoint (week 26; <styled-content style="fixed-case">LOCF</styled-content>) (mmol/l). <styled-content style="fixed-case">AB</styled-content>, after breakfast; <styled-content style="fixed-case">AD</styled-content>, after dinner; <styled-content style="fixed-case">AL</styled-content>, after lunch; <styled-content style="fixed-case">BB</styled-content>, before breakfast; <styled-content style="fixed-case">BD</styled-content>, before dinner; <styled-content style="fixed-case">BL</styled-content>, before lunch; <styled-content style="fixed-case">BT</styled-content>, bedtime; <styled-content style="fixed-case">FSG</styled-content>, fasting serum glucose; <styled-content style="fixed-case">HbA1c</styled-content>, glycated haemoglobin; <styled-content style="fixed-case">LOCF</styled-content>, last observation carried forward; <styled-content style="fixed-case">LSM</styled-content>, least&#x02010;squares mean; s.e., standard error; <styled-content style="fixed-case">SMBG</styled-content>, self&#x02010;monitored blood glucose. *p&#x02009;&#x0003c;&#x02009;0.001 dulaglutide vs placebo.</p></caption><graphic id="nlm-graphic-5" xlink:href="DOM-17-974-g003"><alt-text>DOM-12534-FIG-0003-c</alt-text></graphic></fig><p id="dom12534-para-0026">At 26&#x02009;weeks (LOCF), a significantly greater proportion of patients on dulaglutide achieved HbA1c &#x0003c;7.0% compared with placebo [dulaglutide, 200/280 (71.4%); placebo, 4/68 (5.9%); p&#x02009;&#x0003c;&#x02009;0.001; Figure <xref rid="dom12534-fig-0003" ref-type="fig">3</xref>B]. A significantly greater proportion of patients on dulaglutide [140/280 (50.0%)] achieved HbA1c &#x02264;6.5% compared with placebo [1/68 (1.5%)] at 26&#x02009;weeks (LOCF; p&#x02009;&#x0003c;&#x02009;0.001; Figure <xref rid="dom12534-fig-0003" ref-type="fig">3</xref>B). Proportions of patients who achieved HbA1c &#x0003c;7.0 and &#x02264;6.5% were similar between dulaglutide and liraglutide at 26&#x02009;weeks [LOCF, 200/280 (71.4%) vs 94/136 (69.1%) and 140/280 (50.0%) vs 67/136 (49.3%), respectively].</p><p id="dom12534-para-0027">The LS mean changes in fasting serum glucose from baseline at week 26 were &#x02212;2.18, &#x02212;2.21 and 0.06&#x02009;mmol/l for dulaglutide, liraglutide and placebo, respectively (Figures <xref rid="dom12534-fig-0002" ref-type="fig">2</xref>B, <xref rid="dom12534-fig-0003" ref-type="fig">3</xref>C); dulaglutide significantly reduced fasting serum glucose compared with placebo at week 26 (p&#x02009;&#x0003c;&#x02009;0.001). Dulaglutide significantly reduced SMBG values from baseline compared with placebo for all measures (seven&#x02010;point profile values, mean SMBG values, 2&#x02010;h excursion values for each meal, and circadian variation; all p&#x02009;&#x0003c;&#x02009;0.05), except for the 2&#x02010;h excursion for the evening meal (Figure <xref rid="dom12534-fig-0003" ref-type="fig">3</xref>D and Table S1). Dulaglutide treatment resulted in similar LS mean decreases from baseline in all SMBG values compared with liraglutide.</p><p id="dom12534-para-0028">Treatment did not result in significant changes in body weight from baseline at week 26 (LS mean changes: dulaglutide, &#x02212;0.02&#x02009;kg; liraglutide, &#x02212;0.36&#x02009;kg; and placebo, &#x02212;0.63&#x02009;kg), and there were no significant differences between groups (Figure <xref rid="dom12534-fig-0002" ref-type="fig">2</xref>C).</p><p id="dom12534-para-0029">Dulaglutide significantly increased the updated homoeostasis model assessment of &#x003b2;&#x02010;cell function from baseline compared with placebo (p&#x02009;&#x0003c;&#x02009;0.001) at week 26 (LOCF); the difference between dulaglutide and liraglutide was not significant. No significant differences were observed between dulaglutide and the other treatment groups for the updated homoeostasis model assessment of insulin sensitivity (Figure S1).</p></sec><sec id="dom12534-sec-0013"><title>Safety</title><p id="dom12534-para-0030">No deaths were reported during the treatment period (Table <xref rid="dom12534-tbl-0002" ref-type="table-wrap">2</xref>). The incidence rates of serious adverse events and treatment&#x02010;emergent adverse events were similar between the groups up to 26&#x02009;weeks (Tables <xref rid="dom12534-tbl-0002" ref-type="table-wrap">2</xref> and S2). The most frequently reported treatment&#x02010;emergent adverse events (&#x02265;5% of patients in any group) are shown in Table <xref rid="dom12534-tbl-0002" ref-type="table-wrap">2</xref>; of these, only decreased appetite was different between dulaglutide and liraglutide [dulaglutide, n&#x02009;=&#x02009;2 (0.7%); liraglutide, n&#x02009;=&#x02009;8 (5.8%); p&#x02009;=&#x02009;0.003].</p><table-wrap id="dom12534-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><p>Safety assessments and vital signs up to 26&#x02009;weeks of treatment</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th rowspan="2" id="dom12534-ent-0077" align="left" valign="bottom" colspan="1"/><th rowspan="2" valign="bottom" id="dom12534-ent-0078" align="left" colspan="1">Dulaglutide 0.75&#x02009;mg (N&#x02009;=&#x02009;280)</th><th rowspan="2" valign="bottom" id="dom12534-ent-0079" align="left" colspan="1">Liraglutide 0.9&#x02009;mg (N&#x02009;=&#x02009;137)</th><th rowspan="2" valign="bottom" id="dom12534-ent-0080" align="left" colspan="1">Placebo (N&#x02009;=&#x02009;70)</th><th colspan="2" align="left" id="dom12534-ent-0081" valign="bottom" rowspan="1">p value</th></tr><tr style="border-bottom:solid 1px #000000"><th id="dom12534-ent-0082" align="left" valign="bottom" rowspan="1" colspan="1">Dulaglutide 0.75&#x02009;mg vs liraglutide 0.9&#x02009;mg</th><th id="dom12534-ent-0083" align="left" valign="bottom" rowspan="1" colspan="1">Dulaglutide 0.75&#x02009;mg vs placebo</th></tr></thead><tbody valign="top"><tr><td id="dom12534-ent-0084" align="left" valign="top" rowspan="1" colspan="1">Deaths</td><td id="dom12534-ent-0085" align="left" valign="top" rowspan="1" colspan="1">0</td><td id="dom12534-ent-0086" align="left" valign="top" rowspan="1" colspan="1">0</td><td id="dom12534-ent-0087" align="left" valign="top" rowspan="1" colspan="1">0</td><td id="dom12534-ent-0088" align="left" valign="top" rowspan="1" colspan="1">N/A</td><td id="dom12534-ent-0089" align="left" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td id="dom12534-ent-0090" align="left" valign="top" rowspan="1" colspan="1">Serious adverse events<xref ref-type="fn" rid="dom12534-note-0003">*</xref>
</td><td id="dom12534-ent-0091" align="left" valign="top" rowspan="1" colspan="1">3 (1.1)</td><td id="dom12534-ent-0092" align="left" valign="top" rowspan="1" colspan="1">2 (1.5)</td><td id="dom12534-ent-0093" align="left" valign="top" rowspan="1" colspan="1">2 (2.9)</td><td id="dom12534-ent-0094" align="left" valign="top" rowspan="1" colspan="1">0.665</td><td id="dom12534-ent-0095" align="left" valign="top" rowspan="1" colspan="1">0.262</td></tr><tr><td id="dom12534-ent-0096" align="left" valign="top" rowspan="1" colspan="1">Patients with at least one treatment&#x02010;emergent adverse event</td><td id="dom12534-ent-0097" align="left" valign="top" rowspan="1" colspan="1">157 (56.1)</td><td id="dom12534-ent-0098" align="left" valign="top" rowspan="1" colspan="1">76 (55.5)</td><td id="dom12534-ent-0099" align="left" valign="top" rowspan="1" colspan="1">39 (55.7)</td><td id="dom12534-ent-0100" align="left" valign="top" rowspan="1" colspan="1">0.917</td><td id="dom12534-ent-0101" align="left" valign="top" rowspan="1" colspan="1">&#x0003e;0.999</td></tr><tr><td colspan="6" align="left" id="dom12534-ent-0102" valign="top" rowspan="1">Treatment&#x02010;emergent adverse events (&#x02265;5% in any group)</td></tr><tr><td style="padding-left:10%" id="dom12534-ent-0103" align="left" valign="top" rowspan="1" colspan="1">Nasopharyngitis</td><td id="dom12534-ent-0104" align="left" valign="top" rowspan="1" colspan="1">37 (13.2)</td><td id="dom12534-ent-0105" align="left" valign="top" rowspan="1" colspan="1">16 (11.7)</td><td id="dom12534-ent-0106" align="left" valign="top" rowspan="1" colspan="1">4 (5.7)</td><td id="dom12534-ent-0107" align="left" valign="top" rowspan="1" colspan="1">0.755</td><td id="dom12534-ent-0108" align="left" valign="top" rowspan="1" colspan="1">0.097</td></tr><tr><td style="padding-left:10%" id="dom12534-ent-0109" align="left" valign="top" rowspan="1" colspan="1">Decreased appetite</td><td id="dom12534-ent-0110" align="left" valign="top" rowspan="1" colspan="1">2 (0.7)</td><td id="dom12534-ent-0111" align="left" valign="top" rowspan="1" colspan="1">8 (5.8)</td><td id="dom12534-ent-0112" align="left" valign="top" rowspan="1" colspan="1">0</td><td id="dom12534-ent-0113" align="left" valign="top" rowspan="1" colspan="1">0.003</td><td id="dom12534-ent-0114" align="left" valign="top" rowspan="1" colspan="1">&#x0003e;0.999</td></tr><tr><td style="padding-left:10%" id="dom12534-ent-0115" align="left" valign="top" rowspan="1" colspan="1">Gastrointestinal disorders</td><td id="dom12534-ent-0116" align="left" valign="top" rowspan="1" colspan="1">61 (21.8)</td><td id="dom12534-ent-0117" align="left" valign="top" rowspan="1" colspan="1">42 (30.7)</td><td id="dom12534-ent-0118" align="left" valign="top" rowspan="1" colspan="1">11 (15.7)</td><td id="dom12534-ent-0119" align="left" valign="top" rowspan="1" colspan="1">0.054</td><td id="dom12534-ent-0120" align="left" valign="top" rowspan="1" colspan="1">0.322</td></tr><tr><td style="padding-left:15%" id="dom12534-ent-0121" align="left" valign="top" rowspan="1" colspan="1">Constipation</td><td id="dom12534-ent-0122" align="left" valign="top" rowspan="1" colspan="1">19 (6.8)</td><td id="dom12534-ent-0123" align="left" valign="top" rowspan="1" colspan="1">8 (5.8)</td><td id="dom12534-ent-0124" align="left" valign="top" rowspan="1" colspan="1">3 (4.3)</td><td id="dom12534-ent-0125" align="left" valign="top" rowspan="1" colspan="1">0.834</td><td id="dom12534-ent-0126" align="left" valign="top" rowspan="1" colspan="1">0.587</td></tr><tr><td style="padding-left:15%" id="dom12534-ent-0127" align="left" valign="top" rowspan="1" colspan="1">Diarrhoea</td><td id="dom12534-ent-0128" align="left" valign="top" rowspan="1" colspan="1">16 (5.7)</td><td id="dom12534-ent-0129" align="left" valign="top" rowspan="1" colspan="1">5 (3.6)</td><td id="dom12534-ent-0130" align="left" valign="top" rowspan="1" colspan="1">1 (1.4)</td><td id="dom12534-ent-0131" align="left" valign="top" rowspan="1" colspan="1">0.477</td><td id="dom12534-ent-0132" align="left" valign="top" rowspan="1" colspan="1">0.212</td></tr><tr><td style="padding-left:15%" id="dom12534-ent-0133" align="left" valign="top" rowspan="1" colspan="1">Nausea</td><td id="dom12534-ent-0134" align="left" valign="top" rowspan="1" colspan="1">15 (5.4)</td><td id="dom12534-ent-0135" align="left" valign="top" rowspan="1" colspan="1">11 (8.0)</td><td id="dom12534-ent-0136" align="left" valign="top" rowspan="1" colspan="1">1 (1.4)</td><td id="dom12534-ent-0137" align="left" valign="top" rowspan="1" colspan="1">0.289</td><td id="dom12534-ent-0138" align="left" valign="top" rowspan="1" colspan="1">0.211</td></tr><tr><td style="padding-left:15%" id="dom12534-ent-0139" align="left" valign="top" rowspan="1" colspan="1">Abdominal distension</td><td id="dom12534-ent-0140" align="left" valign="top" rowspan="1" colspan="1">6 (2.1)</td><td id="dom12534-ent-0141" align="left" valign="top" rowspan="1" colspan="1">7 (5.1)</td><td id="dom12534-ent-0142" align="left" valign="top" rowspan="1" colspan="1">0</td><td id="dom12534-ent-0143" align="left" valign="top" rowspan="1" colspan="1">0.133</td><td id="dom12534-ent-0144" align="left" valign="top" rowspan="1" colspan="1">0.604</td></tr><tr><td id="dom12534-ent-0145" align="left" valign="top" rowspan="1" colspan="1">Patients who discontinued study due to an adverse event</td><td id="dom12534-ent-0146" align="left" valign="top" rowspan="1" colspan="1">3 (1.1)</td><td id="dom12534-ent-0147" align="left" valign="top" rowspan="1" colspan="1">1 (0.7)</td><td id="dom12534-ent-0148" align="left" valign="top" rowspan="1" colspan="1">0</td><td id="dom12534-ent-0149" align="left" valign="top" rowspan="1" colspan="1">&#x0003e;0.999</td><td id="dom12534-ent-0150" align="left" valign="top" rowspan="1" colspan="1">&#x0003e;0.999</td></tr><tr><td colspan="6" align="left" id="dom12534-ent-0151" valign="top" rowspan="1">Vital signs, mean change from baseline (s.e.)<xref ref-type="fn" rid="dom12534-note-0004">&#x02020;</xref>
</td></tr><tr><td style="padding-left:10%" id="dom12534-ent-0152" align="left" valign="top" rowspan="1" colspan="1">Seated systolic blood pressure, mmHg</td><td id="dom12534-ent-0153" align="left" valign="top" rowspan="1" colspan="1">0.62 (0.62)</td><td id="dom12534-ent-0154" align="left" valign="top" rowspan="1" colspan="1">&#x02212;2.10 (0.89)</td><td id="dom12534-ent-0155" align="left" valign="top" rowspan="1" colspan="1">0.53 (1.25)</td><td id="dom12534-ent-0156" align="left" valign="top" rowspan="1" colspan="1">0.013</td><td id="dom12534-ent-0157" align="left" valign="top" rowspan="1" colspan="1">0.944</td></tr><tr><td style="padding-left:10%" id="dom12534-ent-0158" align="left" valign="top" rowspan="1" colspan="1">Seated diastolic blood pressure, mmHg</td><td id="dom12534-ent-0159" align="left" valign="top" rowspan="1" colspan="1">1.09 (0.39)</td><td id="dom12534-ent-0160" align="left" valign="top" rowspan="1" colspan="1">0.43 (0.56)</td><td id="dom12534-ent-0161" align="left" valign="top" rowspan="1" colspan="1">0.29 (0.78)</td><td id="dom12534-ent-0162" align="left" valign="top" rowspan="1" colspan="1">0.336</td><td id="dom12534-ent-0163" align="left" valign="top" rowspan="1" colspan="1">0.360</td></tr><tr><td style="padding-left:10%" id="dom12534-ent-0164" align="left" valign="top" rowspan="1" colspan="1">Seated pulse rate, bpm</td><td id="dom12534-ent-0165" align="left" valign="top" rowspan="1" colspan="1">3.35 (0.45)</td><td id="dom12534-ent-0166" align="left" valign="top" rowspan="1" colspan="1">4.77 (0.64)</td><td id="dom12534-ent-0167" align="left" valign="top" rowspan="1" colspan="1">1.49 (0.90)</td><td id="dom12534-ent-0168" align="left" valign="top" rowspan="1" colspan="1">0.070</td><td id="dom12534-ent-0169" align="left" valign="top" rowspan="1" colspan="1">0.064</td></tr><tr><td id="dom12534-ent-0170" align="left" valign="top" rowspan="1" colspan="1">ECG PR interval mean change from baseline (s.e.)<xref ref-type="fn" rid="dom12534-note-0004">&#x02020;</xref>, ms</td><td id="dom12534-ent-0171" align="left" valign="top" rowspan="1" colspan="1">2.20 (0.60)</td><td id="dom12534-ent-0172" align="left" valign="top" rowspan="1" colspan="1">2.07 (0.88)</td><td id="dom12534-ent-0173" align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.45 (1.22)</td><td id="dom12534-ent-0174" align="left" valign="top" rowspan="1" colspan="1">0.899</td><td id="dom12534-ent-0175" align="left" valign="top" rowspan="1" colspan="1">0.052</td></tr><tr><td colspan="6" align="left" id="dom12534-ent-0176" valign="top" rowspan="1">Pancreatic enzymes, median change (IQR)</td></tr><tr><td style="padding-left:10%" id="dom12534-ent-0177" align="left" valign="top" rowspan="1" colspan="1">Total amylase, U/l<xref ref-type="fn" rid="dom12534-note-0005">&#x02021;</xref>
</td><td id="dom12534-ent-0178" align="left" valign="top" rowspan="1" colspan="1">7.0 (2.0&#x02013;15.0)</td><td id="dom12534-ent-0179" align="left" valign="top" rowspan="1" colspan="1">7.0 (1.0&#x02013;15.0)</td><td id="dom12534-ent-0180" align="left" valign="top" rowspan="1" colspan="1">0.0 (&#x02212;6.0&#x02013;6.0)</td><td id="dom12534-ent-0181" align="left" valign="top" rowspan="1" colspan="1">0.605</td><td id="dom12534-ent-0182" align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td style="padding-left:10%" id="dom12534-ent-0183" align="left" valign="top" rowspan="1" colspan="1">Lipase, U/l<xref ref-type="fn" rid="dom12534-note-0005">&#x02021;</xref>
</td><td id="dom12534-ent-0184" align="left" valign="top" rowspan="1" colspan="1">7.0 (1.0&#x02013;13.0)</td><td id="dom12534-ent-0185" align="left" valign="top" rowspan="1" colspan="1">11.0 (5.0&#x02013;21.0)</td><td id="dom12534-ent-0186" align="left" valign="top" rowspan="1" colspan="1">1.0 (&#x02212;6.0&#x02013;5.0)</td><td id="dom12534-ent-0187" align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td><td id="dom12534-ent-0188" align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td colspan="6" align="left" id="dom12534-ent-0189" valign="top" rowspan="1">Patients with treatment&#x02010;emergent abnormal changes in pancreatic enzymes (&#x0003e;ULN)</td></tr><tr><td style="padding-left:10%" id="dom12534-ent-0190" align="left" valign="top" rowspan="1" colspan="1">Total amylase<xref ref-type="fn" rid="dom12534-note-0006">&#x000a7;</xref>
</td><td id="dom12534-ent-0191" align="left" valign="top" rowspan="1" colspan="1">11/261 (4.2)</td><td id="dom12534-ent-0192" align="left" valign="top" rowspan="1" colspan="1">8/124 (6.5)</td><td id="dom12534-ent-0193" align="left" valign="top" rowspan="1" colspan="1">4/62 (6.5)</td><td id="dom12534-ent-0194" align="left" valign="top" rowspan="1" colspan="1">0.450</td><td id="dom12534-ent-0195" align="left" valign="top" rowspan="1" colspan="1">0.500</td></tr><tr><td style="padding-left:10%" id="dom12534-ent-0196" align="left" valign="top" rowspan="1" colspan="1">Lipase<xref ref-type="fn" rid="dom12534-note-0006">&#x000a7;</xref>
</td><td id="dom12534-ent-0197" align="left" valign="top" rowspan="1" colspan="1">47/254 (18.5)</td><td id="dom12534-ent-0198" align="left" valign="top" rowspan="1" colspan="1">36/121 (29.8)</td><td id="dom12534-ent-0199" align="left" valign="top" rowspan="1" colspan="1">3/61 (4.9)</td><td id="dom12534-ent-0200" align="left" valign="top" rowspan="1" colspan="1">0.017</td><td id="dom12534-ent-0201" align="left" valign="top" rowspan="1" colspan="1">0.006</td></tr><tr><td colspan="6" align="left" id="dom12534-ent-0202" valign="top" rowspan="1">Patients with pancreatic enzyme concentration &#x0003e;3&#x02009;&#x000d7;&#x02009;ULN</td></tr><tr><td style="padding-left:10%" id="dom12534-ent-0203" align="left" valign="top" rowspan="1" colspan="1">Total amylase</td><td id="dom12534-ent-0204" align="left" valign="top" rowspan="1" colspan="1">0</td><td id="dom12534-ent-0205" align="left" valign="top" rowspan="1" colspan="1">0</td><td id="dom12534-ent-0206" align="left" valign="top" rowspan="1" colspan="1">1 (1.5)</td><td id="dom12534-ent-0207" align="left" valign="top" rowspan="1" colspan="1">N/A</td><td id="dom12534-ent-0208" align="left" valign="top" rowspan="1" colspan="1">0.191</td></tr><tr><td style="padding-left:10%" id="dom12534-ent-0209" align="left" valign="top" rowspan="1" colspan="1">Lipase</td><td id="dom12534-ent-0210" align="left" valign="top" rowspan="1" colspan="1">4 (1.5)</td><td id="dom12534-ent-0211" align="left" valign="top" rowspan="1" colspan="1">2 (1.5)</td><td id="dom12534-ent-0212" align="left" valign="top" rowspan="1" colspan="1">0</td><td id="dom12534-ent-0213" align="left" valign="top" rowspan="1" colspan="1">1.000</td><td id="dom12534-ent-0214" align="left" valign="top" rowspan="1" colspan="1">1.000</td></tr><tr><td colspan="6" align="left" id="dom12534-ent-0215" valign="top" rowspan="1">Treatment&#x02010;emergent dulaglutide antidrug antibodies<xref ref-type="fn" rid="dom12534-note-0007">&#x000b6;</xref>
</td></tr><tr><td style="padding-left:10%" id="dom12534-ent-0216" align="left" valign="top" rowspan="1" colspan="1">Dulaglutide antidrug antibodies</td><td id="dom12534-ent-0217" align="left" valign="top" rowspan="1" colspan="1">3 (1.1)</td><td id="dom12534-ent-0218" align="left" valign="top" rowspan="1" colspan="1">0</td><td id="dom12534-ent-0219" align="left" valign="top" rowspan="1" colspan="1">0</td><td id="dom12534-ent-0220" align="left" valign="top" rowspan="1" colspan="1">N/A</td><td id="dom12534-ent-0221" align="left" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td style="padding-left:10%" id="dom12534-ent-0222" align="left" valign="top" rowspan="1" colspan="1">Dulaglutide neutralising antidrug antibodies</td><td id="dom12534-ent-0223" align="left" valign="top" rowspan="1" colspan="1">0</td><td id="dom12534-ent-0224" align="left" valign="top" rowspan="1" colspan="1">0</td><td id="dom12534-ent-0225" align="left" valign="top" rowspan="1" colspan="1">0</td><td id="dom12534-ent-0226" align="left" valign="top" rowspan="1" colspan="1">N/A</td><td id="dom12534-ent-0227" align="left" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td style="padding-left:10%" id="dom12534-ent-0228" align="left" valign="top" rowspan="1" colspan="1">nsGLP&#x02010;1 cross&#x02010;reactive antibodies</td><td id="dom12534-ent-0229" align="left" valign="top" rowspan="1" colspan="1">2 (0.7)</td><td id="dom12534-ent-0230" align="left" valign="top" rowspan="1" colspan="1">0</td><td id="dom12534-ent-0231" align="left" valign="top" rowspan="1" colspan="1">0</td><td id="dom12534-ent-0232" align="left" valign="top" rowspan="1" colspan="1">N/A</td><td id="dom12534-ent-0233" align="left" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td style="padding-left:10%" id="dom12534-ent-0234" align="left" valign="top" rowspan="1" colspan="1">nsGLP&#x02010;1 neutralizing antibodies</td><td id="dom12534-ent-0235" align="left" valign="top" rowspan="1" colspan="1">0</td><td id="dom12534-ent-0236" align="left" valign="top" rowspan="1" colspan="1">0</td><td id="dom12534-ent-0237" align="left" valign="top" rowspan="1" colspan="1">0</td><td id="dom12534-ent-0238" align="left" valign="top" rowspan="1" colspan="1">N/A</td><td id="dom12534-ent-0239" align="left" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td style="padding-left:10%" id="dom12534-ent-0240" align="left" valign="top" rowspan="1" colspan="1">Both nsGLP&#x02010;1 neutralizing and cross&#x02010;reactive antibodies</td><td id="dom12534-ent-0241" align="left" valign="top" rowspan="1" colspan="1">0</td><td id="dom12534-ent-0242" align="left" valign="top" rowspan="1" colspan="1">0</td><td id="dom12534-ent-0243" align="left" valign="top" rowspan="1" colspan="1">0</td><td id="dom12534-ent-0244" align="left" valign="top" rowspan="1" colspan="1">N/A</td><td id="dom12534-ent-0245" align="left" valign="top" rowspan="1" colspan="1">N/A</td></tr></tbody></table><table-wrap-foot><fn id="dom12534-note-0002"><p>Data are n (%) unless otherwise specified. Treatment&#x02010;emergent adverse events coded using <styled-content style="fixed-case">MedDRA V</styled-content>ersion 16.1. <styled-content style="fixed-case">IQR</styled-content>, interquartile range; <styled-content style="fixed-case">MedDRA</styled-content>, <styled-content style="fixed-case">M</styled-content>edical <styled-content style="fixed-case">D</styled-content>ictionary for <styled-content style="fixed-case">R</styled-content>egulatory <styled-content style="fixed-case">A</styled-content>ctivities; <styled-content style="fixed-case">N</styled-content>, number of patients in safety analysis set; <styled-content style="fixed-case">N/A</styled-content>, not applicable; <styled-content style="fixed-case">nsGLP&#x02010;1</styled-content>, native&#x02010;sequence glucagon&#x02010;like peptide&#x02010;1; s.e., standard error; <styled-content style="fixed-case">ULN</styled-content>, upper limit of normal.</p></fn><fn id="dom12534-note-0003"><label>*</label><p>Reported serious adverse events are listed in Table S2.</p></fn><fn id="dom12534-note-0004"><label>&#x02020;</label><p>Data are least&#x02010;squares mean change (s.e.).</p></fn><fn id="dom12534-note-0005"><label>&#x02021;</label><p>Data are <styled-content style="fixed-case">LOCF</styled-content>, median change (<styled-content style="fixed-case">IQR</styled-content>).</p></fn><fn id="dom12534-note-0006"><label>&#x000a7;</label><p>Data represent the number of patients with treatment&#x02010;emergent abnormal change in pancreatic enzymes at week 26 over the number of patients with normal results at baseline.</p></fn><fn id="dom12534-note-0007"><label>&#x000b6;</label><p>These values include all postbaseline observations including the safety follow&#x02010;up.</p></fn></table-wrap-foot></table-wrap><p id="dom12534-para-0031">One patient, in the dulaglutide group, reported severe constipation; all other treatment&#x02010;emergent gastrointestinal adverse events up to week 26 were considered to be of mild or moderate intensity. The numbers of patients in each group who discontinued the study because of an adverse event were dulaglutide, n&#x02009;=&#x02009;3 (1.1%), liraglutide, n&#x02009;=&#x02009;1 (0.7%) and placebo, n&#x02009;=&#x02009;0 (Table <xref rid="dom12534-tbl-0002" ref-type="table-wrap">2</xref>). Six patients discontinued the study drug within the first 26&#x02009;weeks of treatment because of treatment&#x02010;emergent gastrointestinal adverse events: dulaglutide, n&#x02009;=&#x02009;1 (gastroenteritis) and liraglutide, n&#x02009;=&#x02009;5 (abdominal discomfort, n&#x02009;=&#x02009;2; constipation, decreased appetite and nausea, n&#x02009;=&#x02009;1 for each).</p><p id="dom12534-para-0032">Up to 26&#x02009;weeks, 9 patients (1.8%) experienced any hypoglycaemia [dulaglutide, n&#x02009;=&#x02009;6 (2.1%); liraglutide, n&#x02009;=&#x02009;2 (1.5%); placebo, n&#x02009;=&#x02009;1 (1.4%)]; no episodes of severe hypoglycaemia were reported. Two patients (0.7%; both dulaglutide) experienced nocturnal hypoglycaemia up to 26&#x02009;weeks.</p><p id="dom12534-para-0033">In a pairwise comparison at 26&#x02009;weeks, dulaglutide significantly increased total amylase and lipase levels compared with placebo (p&#x02009;&#x0003c;&#x02009;0.001; Table <xref rid="dom12534-tbl-0002" ref-type="table-wrap">2</xref>). No difference was observed between dulaglutide and liraglutide in changes in total amylase level. Liraglutide significantly increased lipase levels compared with dulaglutide (median increases were 11.0 and 7.0&#x02009;U/l, respectively; p&#x02009;&#x0003c;&#x02009;0.001; Table <xref rid="dom12534-tbl-0002" ref-type="table-wrap">2</xref>). No patients in the dulaglutide or liraglutide groups had amylase levels &#x0003e;3&#x02009;&#x000d7;&#x02009;upper limit of normal (ULN; Table <xref rid="dom12534-tbl-0002" ref-type="table-wrap">2</xref>). Four (1.5%) patients in the dulaglutide group and 2 (1.5%) in the liraglutide group had lipase levels &#x0003e;3&#x02009;&#x000d7;&#x02009;ULN; the elevated values decreased below 3&#x02009;&#x000d7;&#x02009;ULN while the patients continued on study medication. None of these patients discontinued study treatment because of pancreatic adverse events. There were no adjudicated events of confirmed pancreatitis.</p><p id="dom12534-para-0034">One patient, a 67&#x02010;year&#x02010;old female who was treated with liraglutide for approximately 15&#x02009;weeks, was diagnosed with pancreatic carcinoma.</p><p id="dom12534-para-0035">Seated vital signs and ECG PR interval are summarized in Table <xref rid="dom12534-tbl-0002" ref-type="table-wrap">2</xref>. There were no differences in systolic or diastolic blood pressure change from baseline between dulaglutide and placebo; liraglutide resulted in a significantly greater decrease from baseline in seated systolic blood pressure compared with dulaglutide (p&#x02009;=&#x02009;0.013). Seated pulse rates were increased in all groups, with no significant differences between the groups. ECG PR interval was prolonged from baseline in dulaglutide compared with placebo (p&#x02009;=&#x02009;0.052); the ECG PR interval increase with liraglutide was similar to dulaglutide. No confirmed adjudicated cardiovascular events were observed.</p><p id="dom12534-para-0036">From baseline up to 26&#x02009;weeks, all patients had serum calcitonin values within normal limits. The patient with pancreatic carcinoma described previously also had a thyroid neoplasm treatment&#x02010;emergent adverse event, which was considered to be of mild severity and not related to study drug by the investigator.</p><p id="dom12534-para-0037">Dulaglutide significantly reduced urine albumin&#x02009;:&#x02009;creatinine ratio (p&#x02009;&#x0003c;&#x02009;0.001) from baseline to 26&#x02009;weeks compared with placebo (Table S3). Dulaglutide treatment resulted in significant percent reductions in triglycerides (&#x02212;8.0%; p&#x02009;=&#x02009;0.020) and total cholesterol (&#x02212;2.9%; p&#x02009;=&#x02009;0.009) from baseline compared with placebo (Table S4).</p><p id="dom12534-para-0038">Three patients in the dulaglutide group had treatment&#x02010;emergent dulaglutide antidrug antibodies (Table <xref rid="dom12534-tbl-0002" ref-type="table-wrap">2</xref>).</p></sec></sec><sec id="dom12534-sec-0014"><title>Discussion</title><p id="dom12534-para-0039">The aim of the present study was to examine the efficacy and safety of once&#x02010;weekly dulaglutide (0.75&#x02009;mg) in Japanese patients with type 2 diabetes. Overall, in the first head&#x02010;to&#x02010;head GLP&#x02010;1 receptor agonist study in Japanese patients with type 2 diabetes, once&#x02010;weekly dulaglutide (0.75&#x02009;mg) was non&#x02010;inferior to once&#x02010;daily liraglutide (0.9&#x02009;mg) and superior to placebo in change from baseline HbA1c.</p><p id="dom12534-para-0040">This is the first study to demonstrate the efficacy and safety of dulaglutide monotherapy in Japanese patients with type 2 diabetes, and these findings may help inform treatment decisions for those patients. This is also the first study in Japanese patients to show non&#x02010;inferiority of once&#x02010;weekly dulaglutide (0.75&#x02009;mg) to once&#x02010;daily liraglutide (0.9&#x02009;mg), the maximum doses evaluated in Japanese phase III registration programmes for these compounds. In other once&#x02010;weekly GLP&#x02010;1 receptor agonist studies DURATION&#x02010;6 [26&#x02009;weeks: exenatide once weekly (AstraZeneca, London, UK)] and HARMONY&#x02010;7 [32&#x02009;weeks: albiglutide (GlaxoSmithKline, Wilmington, DE, USA)], neither exenatide once weekly nor albiglutide demonstrated non&#x02010;inferiority to liraglutide (1.8&#x02009;mg) on HbA1c change from baseline values [LS mean differences 0.21% (95% CI 0.08, 0.33), non&#x02010;inferiority margin of 0.25%; and 0.21% (95% CI 0.08, 0.34), non&#x02010;inferiority margin of 0.3%, respectively] <xref rid="dom12534-bib-0017" ref-type="ref">17</xref>, <xref rid="dom12534-bib-0018" ref-type="ref">18</xref>. AWARD&#x02010;6 (26&#x02009;weeks: dulaglutide 1.5&#x02009;mg) has been the only phase III study to date to demonstrate non&#x02010;inferiority to liraglutide (1.8&#x02009;mg) on HbA1c change from baseline measurements, in mainly Caucasian patients with type 2 diabetes [LS mean difference &#x02212;0.06% (95% CI &#x02212;0.19, 0.07), with a non&#x02010;inferiority margin of 0.4%] <xref rid="dom12534-bib-0012" ref-type="ref">12</xref>.</p><p id="dom12534-para-0041">The HbA1c reduction observed at 26&#x02009;weeks in the present study in Japanese patients with type 2 diabetes is consistent with the upper range of reductions seen in the global AWARD studies for dulaglutide (0.75 or 1.5&#x02009;mg) <xref rid="dom12534-bib-0011" ref-type="ref">11</xref>, <xref rid="dom12534-bib-0012" ref-type="ref">12</xref>, <xref rid="dom12534-bib-0013" ref-type="ref">13</xref>, <xref rid="dom12534-bib-0014" ref-type="ref">14</xref>. It has been previously reported that GLP&#x02010;1 receptor agonists exert greater HbA1c&#x02010;lowering effects in Asian compared with non&#x02010;Asian people, and it has been suggested that differences in BMI between the ethnicities may be a contributing factor in the observed differential effects <xref rid="dom12534-bib-0019" ref-type="ref">19</xref>. In the present study, once&#x02010;weekly dulaglutide (0.75&#x02009;mg) resulted in approximately 70 and 50% of patients achieving HbA1c targets of &#x0003c;7.0 or &#x02264;6.5% at week 26 (LOCF), respectively. These results were also consistent with a phase II study of dulaglutide in Japanese patients <xref rid="dom12534-bib-0020" ref-type="ref">20</xref>.</p><p id="dom12534-para-0042">It has been reported that Japanese patients with type 2 diabetes tend to have a pathophysiology of insulin secretion impairment rather than insulin resistance and are inclined to be less obese compared with Western populations <xref rid="dom12534-bib-0021" ref-type="ref">21</xref>. Because GLP&#x02010;1 receptor agonists have a potential for improving &#x003b2;&#x02010;cell function and increasing insulin secretion, this class may be particularly effective in lean East&#x02010;Asian patients with type 2 diabetes. In the present study, both dulaglutide and liraglutide resulted in improvement in &#x003b2;&#x02010;cell function, consistent with previous reports for liraglutide 0.9&#x02009;mg in a study of Japanese patients with type 2 diabetes <xref rid="dom12534-bib-0022" ref-type="ref">22</xref>.</p><p id="dom12534-para-0043">Notably, there was no clinically relevant reduction in weight in any group over the 26&#x02010;week period. This was not unexpected and is consistent with observations in studies of liraglutide (0.9&#x02009;mg) in Japanese patients <xref rid="dom12534-bib-0023" ref-type="ref">23</xref>, <xref rid="dom12534-bib-0024" ref-type="ref">24</xref>. The reason for this is unclear. One could speculate that it might be related to concomitant background medications or to lower baseline body weights in the Japanese population, or that it might be an effect of improvement in &#x003b2;&#x02010;cell function, as described below. The mean baseline body weight was approximately 70&#x02009;kg (mean BMI 25.6&#x02009;kg/m<sup>2</sup>), which is typical of Japanese patients with type 2 diabetes and lower than in Caucasian patients. In such patients, dulaglutide improved HbA1c regardless of weight change during treatment, possibly through improvement in &#x003b2;&#x02010;cell function rather than insulin resistance.</p><p id="dom12534-para-0044">Overall, once&#x02010;weekly dulaglutide (0.75&#x02009;mg) was generally well tolerated, with a low number of overall discontinuations in each group. The safety profile of dulaglutide in this study (Table <xref rid="dom12534-tbl-0002" ref-type="table-wrap">2</xref>) was similar to that seen in previous GLP&#x02010;1 receptor agonist studies <xref rid="dom12534-bib-0011" ref-type="ref">11</xref>, <xref rid="dom12534-bib-0012" ref-type="ref">12</xref>, <xref rid="dom12534-bib-0013" ref-type="ref">13</xref>, <xref rid="dom12534-bib-0014" ref-type="ref">14</xref>, <xref rid="dom12534-bib-0017" ref-type="ref">17</xref>, <xref rid="dom12534-bib-0018" ref-type="ref">18</xref>. The most&#x02010;frequently reported adverse event was nasopharyngitis, reported by 12&#x02013;13% of patients in the active treatment groups. The incidence of nasopharyngitis in this study was not considered clinically relevant, and the difference between the treatment groups was not statistically significant. The incidence of gastrointestinal symptoms was also similar between dulaglutide and liraglutide. Nausea was transient and occurred most often during the first 2&#x02009;weeks of treatment. Notably, decreased appetite occurred significantly more often with liraglutide than with dulaglutide. The incidence of hypoglycaemia was similar between the groups and very low as a whole, with no events of severe hypoglycaemia observed. These results are similar to those seen in the class <xref rid="dom12534-bib-0011" ref-type="ref">11</xref>, <xref rid="dom12534-bib-0012" ref-type="ref">12</xref>, <xref rid="dom12534-bib-0013" ref-type="ref">13</xref>, <xref rid="dom12534-bib-0014" ref-type="ref">14</xref>, <xref rid="dom12534-bib-0017" ref-type="ref">17</xref>, <xref rid="dom12534-bib-0018" ref-type="ref">18</xref>, <xref rid="dom12534-bib-0019" ref-type="ref">19</xref>, <xref rid="dom12534-bib-0023" ref-type="ref">23</xref>, indicating that GLP&#x02010;1 receptor agonists, including dulaglutide, when used as monotherapy, show a low propensity to cause hypoglycaemia.</p><p id="dom12534-para-0045">Vital signs at week 26 showed mean increases in seated pulse rate in the dulaglutide and liraglutide groups, and these changes appear to be a GLP&#x02010;1 receptor agonist class effect <xref rid="dom12534-bib-0025" ref-type="ref">25</xref>.</p><p id="dom12534-para-0046">Compared with placebo, dulaglutide resulted in statistically significant increases in amylase and lipase levels at week 26. Liraglutide resulted in a statistically significant increase in lipase level compared with dulaglutide. These findings are also consistent with a recent meta&#x02010;analysis of GLP&#x02010;1 receptor agonist clinical trials <xref rid="dom12534-bib-0026" ref-type="ref">26</xref>. These types of elevations were not predictive of pancreatitis during the dulaglutide global development programme <xref rid="dom12534-bib-0011" ref-type="ref">11</xref>, <xref rid="dom12534-bib-0012" ref-type="ref">12</xref>, <xref rid="dom12534-bib-0013" ref-type="ref">13</xref>, <xref rid="dom12534-bib-0014" ref-type="ref">14</xref>; however, the long&#x02010;term clinical significance of these elevations remains unclear. Acute pancreatitis was not observed in the present study.</p><p id="dom12534-para-0047">The urine albumin&#x02009;:&#x02009;creatinine ratio and triglyceride levels were both decreased with dulaglutide and liraglutide. These pleiotropic effects might be a class effect of GLP&#x02010;1 receptor agonists. A recent report showed that liraglutide protected against albuminuria in streptozotocin&#x02010;induced diabetic rats in a protein kinase A&#x02010;mediated manner, which was not related to lowered glucose levels <xref rid="dom12534-bib-0027" ref-type="ref">27</xref>. Meier et&#x02009;al. <xref rid="dom12534-bib-0028" ref-type="ref">28</xref> and Xiao et&#x02009;al. <xref rid="dom12534-bib-0029" ref-type="ref">29</xref> have reported that GLP&#x02010;1 improves postprandial lipidaemia because of delayed gastric emptying and insulin&#x02010;mediated inhibition of lipolysis and intestinal lipoprotein production. The combined effects of lowered urine albumin&#x02009;:&#x02009;creatinine ratio, triglycerides and cholesterol levels with dulaglutide treatment may provide protection against cardiovascular disease. GLP&#x02010;1 receptor agonists also exhibit numerous overlapping and distinct actions in the cardiovascular system <xref rid="dom12534-bib-0030" ref-type="ref">30</xref>, <xref rid="dom12534-bib-0031" ref-type="ref">31</xref>. Several studies of cardiovascular event outcomes after treatment with GLP&#x02010;1 receptor agonists are currently ongoing; the results will provide more information on the clinical relevance of GLP&#x02010;1 receptor agonist treatment with regard to the cardiovascular system.</p><p id="dom12534-para-0048">Three (1.1%) patients in the dulaglutide group and no patients in the liraglutide or placebo groups had treatment&#x02010;emergent dulaglutide antidrug antibodies detected. The incidence of antibodies in the present study was lower than in other GLP&#x02010;1 compounds with an exendin&#x02010;4 backbone (exenatide twice daily, 44&#x02013;60% <xref rid="dom12534-bib-0032" ref-type="ref">32</xref>; exenatide once weekly, 61&#x02013;68% <xref rid="dom12534-bib-0033" ref-type="ref">33</xref>, <xref rid="dom12534-bib-0034" ref-type="ref">34</xref>; and lixisenatide, approximately 70% <xref rid="dom12534-bib-0035" ref-type="ref">35</xref>); the lower incidence in the present study is probably attributable to the design of the dulaglutide molecule <xref rid="dom12534-bib-0036" ref-type="ref">36</xref>.</p><p id="dom12534-para-0049">The present study has several limitations. An open&#x02010;label format for liraglutide was used because placebo pens mimicking liraglutide were not commercially available. The length of the study was relatively short in clinical practice with type 2 diabetes; however, the 26&#x02010;week primary endpoint was long enough to reach steady&#x02010;state in order to evaluate the dulaglutide treatment effect for the primary and secondary objectives on HbA1c. This randomized, controlled study continued for another 26&#x02010;week period, during which all patients on placebo were switched to dulaglutide to gather further safety data; these results will be reported at a later date.</p><p id="dom12534-para-0050">In conclusion, monotherapy with once&#x02010;weekly dulaglutide (0.75&#x02009;mg) was safe and effective in Japanese patients with type 2 diabetes and resulted in similar safety and efficacy profiles compared with once&#x02010;daily liraglutide (0.9&#x02009;mg).</p></sec><sec id="dom12534-sec-0016"><title>Conflict of Interest</title><p id="dom12534-para-0052">All authors participated in reviewing and interpreting the data and providing comments and revisions to the manuscript. All authors approved the final version of the manuscript and take full responsibility for the content. J. M. was a trial investigator, participated in data collection, and has received: grants from Boehringer Ingelheim and Eli Lilly; and research support from Astra Zeneca, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Kowa Pharmaceutical, Novartis Pharma, Ono Pharmaceutical and Sanwa Kagaku Kenkyusho. M. O. was a trial investigator, participated in data collection, and has received: grants from Eli Lilly, Novo Nordisk and Sanofi; advisory panel fees from Eli Lilly, Novo Nordisk and Sanofi; research support from Eli Lilly, Novo Nordisk and Sanofi; and speaker's bureau fees from Eli Lilly, Novo Nordisk and Sanofi. T. T. was a trial investigator, participated in data collection, and has received a grant from Eli Lilly and speaker's bureau fees from Eli Lilly and Novo Nordisk. N. I. prepared the first draft of the manuscript, was responsible for trial design and medical oversight during the trial, and is an employee of Eli Lilly Japan K.K. Y. T. prepared the first draft of the manuscript, was responsible for the statistical consideration in the analysis and trial design, and is an employee of Eli Lilly Japan K.K. T. I. prepared the first draft of the manuscript, was responsible for trial design and medical oversight during the trial, crafted the discussion and research context, is an employee of Eli Lilly Japan K.K. and has the company stock option.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data" id="dom12534-supitem-0001"><caption><p>
<bold>Figure S1.</bold> Updated homeostasis model assessment changes from baseline at 26&#x02009;weeks (LOCF).</p></caption><media xlink:href="DOM-17-974-s001.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="dom12534-supitem-0002"><caption><p>
<bold>Table S1.</bold> Summary of least squares&#x02009;(&#x000b1;&#x02009;standard error) mean changes from baseline in self&#x02010;monitored blood glucose (mmol/l) values (LOCF at week 26).</p></caption><media xlink:href="DOM-17-974-s002.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="dom12534-supitem-0003"><caption><p>
<bold>Table S2.</bold> Summary of serious adverse events by preferred term and treatment for the treatment period from baseline to 26&#x02009;weeks.</p></caption><media xlink:href="DOM-17-974-s003.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="dom12534-supitem-0004"><caption><p>
<bold>Table S3.</bold> Summary and analysis of renal analytes: median baseline values and median changes from baseline to 26&#x02009;weeks (LOCF).</p></caption><media xlink:href="DOM-17-974-s004.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="dom12534-supitem-0005"><caption><p>
<bold>Table S4.</bold> Summary and analysis of lipid profiles: median baseline values and median absolute and percent changes from baseline to 26&#x02009;weeks (LOCF).</p></caption><media xlink:href="DOM-17-974-s005.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="dom12534-sec-0015"><title>Acknowledgements</title><p id="dom12534-para-0051">The trial was sponsored by Eli Lilly and Company. We would like to thank the study investigators, staff, and participants for their needed contributions. We would also like to thank Miwa Sakaridani for clinical trial management of the study. The authors would like to thank David Meats (inVentiv Health Clinical) for his medical writing contributions for the submission of this manuscript.</p></ack><ref-list content-type="cited-references" id="dom12534-bibl-0001"><title>References</title><ref id="dom12534-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="dom12534-cit-0001">
<string-name>
<surname>Anini</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Brubaker</surname>
<given-names>PL</given-names>
</string-name>. <article-title>Muscarinic receptors control glucagon&#x02010;like peptide 1 secretion by human endocrine L cells</article-title>. <source>Endocrinology</source>
<year>2003</year>; <volume>144</volume>: <fpage>3244</fpage>&#x02013;<lpage>3250</lpage>.<pub-id pub-id-type="pmid">12810581</pub-id></mixed-citation></ref><ref id="dom12534-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="dom12534-cit-0002">
<string-name>
<surname>Parkes</surname>
<given-names>DG</given-names>
</string-name>, <string-name>
<surname>Pittner</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Jodka</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Smith</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Young</surname>
<given-names>A</given-names>
</string-name>. <article-title>Insulinotropic actions of exendin&#x02010;4 and glucagon&#x02010;like peptide&#x02010;1 in vivo and in vitro</article-title>. <source>Metabolism</source>
<year>2001</year>; <volume>50</volume>: <fpage>583</fpage>&#x02013;<lpage>589</lpage>.<pub-id pub-id-type="pmid">11319721</pub-id></mixed-citation></ref><ref id="dom12534-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="dom12534-cit-0003">
<string-name>
<surname>Drucker</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Nauck</surname>
<given-names>MA</given-names>
</string-name>. <article-title>The incretin system: glucagon&#x02010;like peptide&#x02010;1 receptor agonists and dipeptidyl peptidase&#x02010;4 inhibitors in type 2 diabetes</article-title>. <source>Lancet</source>
<year>2006</year>; <volume>368</volume>: <fpage>1696</fpage>&#x02013;<lpage>1705</lpage>.<pub-id pub-id-type="pmid">17098089</pub-id></mixed-citation></ref><ref id="dom12534-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="dom12534-cit-0004">
<string-name>
<surname>Creutzfeldt</surname>
<given-names>WO</given-names>
</string-name>, <string-name>
<surname>Kleine</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Willms</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Orskov</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Holst</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Nauck</surname>
<given-names>MA</given-names>
</string-name>. <article-title>Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon&#x02010;like peptide I(7&#x02013;36) amide in type I diabetic patients</article-title>. <source>Diabetes Care</source>
<year>1996</year>; <volume>19</volume>: <fpage>580</fpage>&#x02013;<lpage>586</lpage>.<pub-id pub-id-type="pmid">8725855</pub-id></mixed-citation></ref><ref id="dom12534-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="dom12534-cit-0005">
<string-name>
<surname>Tong</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>D'Alessio</surname>
<given-names>D</given-names>
</string-name>. <article-title>Give the receptor a brake: slowing gastric emptying by GLP&#x02010;1</article-title>. <source>Diabetes</source>
<year>2014</year>; <volume>63</volume>: <fpage>407</fpage>&#x02013;<lpage>409</lpage>.<pub-id pub-id-type="pmid">24464721</pub-id></mixed-citation></ref><ref id="dom12534-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="dom12534-cit-0006">
<string-name>
<surname>Turton</surname>
<given-names>MD</given-names>
</string-name>, <string-name>
<surname>O'Shea</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Gunn</surname>
<given-names>I</given-names>
</string-name> et&#x02009;al. <article-title>A role for glucagon&#x02010;like peptide&#x02010;1 in the central regulation of feeding</article-title>. <source>Nature</source>
<year>1996</year>; <volume>379</volume>: <fpage>69</fpage>&#x02013;<lpage>72</lpage>.<pub-id pub-id-type="pmid">8538742</pub-id></mixed-citation></ref><ref id="dom12534-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="dom12534-cit-0007">
<string-name>
<surname>Gutzwiller</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Drewe</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>G&#x000f6;ke</surname>
<given-names>B</given-names>
</string-name> et&#x02009;al. <article-title>Glucagon&#x02010;like peptide&#x02010;1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2</article-title>. <source>Am J Physiol</source>
<year>1999</year>; <volume>276</volume>: <fpage>R1541</fpage>&#x02013;<lpage>1544</lpage>.<pub-id pub-id-type="pmid">10233049</pub-id></mixed-citation></ref><ref id="dom12534-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="dom12534-cit-0008">
<string-name>
<surname>Meier</surname>
<given-names>JJ</given-names>
</string-name>. <article-title>GLP&#x02010;1 receptor agonists for individualized treatment of type 2 diabetes mellitus</article-title>. <source>Nat Rev Endocrinol</source>
<year>2012</year>; <volume>8</volume>: <fpage>728</fpage>&#x02013;<lpage>742</lpage>.<pub-id pub-id-type="pmid">22945360</pub-id></mixed-citation></ref><ref id="dom12534-bib-0009"><label>9</label><mixed-citation publication-type="miscellaneous" id="dom12534-cit-0009">
<collab collab-type="authors" id="dom12534-gp-0001">Eli Lilly and Company</collab>
. <article-title>Trulicity [Prescribing information]</article-title>. <year>2014</year> Available from URL: <ext-link ext-link-type="uri" xlink:href="http://pi.lilly.com/us/trulicity-uspi.pdf">http://pi.lilly.com/us/trulicity-uspi.pdf</ext-link>. Accessed 11 March 2015.</mixed-citation></ref><ref id="dom12534-bib-0010"><label>10</label><mixed-citation publication-type="miscellaneous" id="dom12534-cit-0010">
<collab collab-type="authors" id="dom12534-gp-0002">Eli Lilly and Company</collab>
. <article-title>Trulicity [Summary of product characteristics]</article-title>. <year>2014</year> Available from URL: <ext-link ext-link-type="uri" xlink:href="http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002825/human_med_001821.jsp&#x00026;mid=WC0b01ac058001d124">http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002825/human_med_001821.jsp&#x00026;mid=WC0b01ac058001d124</ext-link>. Accessed 11 March 2015.</mixed-citation></ref><ref id="dom12534-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="dom12534-cit-0011">
<string-name>
<surname>Nauck</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Weinstock</surname>
<given-names>RS</given-names>
</string-name>, <string-name>
<surname>Umpierrez</surname>
<given-names>GE</given-names>
</string-name>, <string-name>
<surname>Guerci</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Skrivanek</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Milicevic</surname>
<given-names>Z</given-names>
</string-name>. <article-title>Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD&#x02010;5)</article-title>. <source>Diabetes Care</source>
<year>2014</year>; <volume>37</volume>: <fpage>2149</fpage>&#x02013;<lpage>2158</lpage>.<pub-id pub-id-type="pmid">24742660</pub-id></mixed-citation></ref><ref id="dom12534-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="dom12534-cit-0012">
<string-name>
<surname>Dungan</surname>
<given-names>KM</given-names>
</string-name>, <string-name>
<surname>Povedano</surname>
<given-names>ST</given-names>
</string-name>, <string-name>
<surname>Forst</surname>
<given-names>T</given-names>
</string-name> et&#x02009;al. <article-title>Once&#x02010;weekly dulaglutide versus once&#x02010;daily liraglutide in metformin&#x02010;treated patients with type 2 diabetes (AWARD&#x02010;6): a randomised, open&#x02010;label, phase 3, non&#x02010;inferiority trial</article-title>. <source>Lancet</source>
<year>2014</year>; <volume>384</volume>: <fpage>1349</fpage>&#x02013;<lpage>1357</lpage>.<pub-id pub-id-type="pmid">25018121</pub-id></mixed-citation></ref><ref id="dom12534-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="dom12534-cit-0013">
<string-name>
<surname>Umpierrez</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Tof&#x000e9; Povedano</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>P&#x000e9;rez Manghi</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Shurzinske</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Pechtner</surname>
<given-names>V</given-names>
</string-name>. <article-title>Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD&#x02010;3)</article-title>. <source>Diabetes Care</source>
<year>2014</year>; <volume>37</volume>: <fpage>2168</fpage>&#x02013;<lpage>2176</lpage>.<pub-id pub-id-type="pmid">24842985</pub-id></mixed-citation></ref><ref id="dom12534-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="dom12534-cit-0014">
<string-name>
<surname>Wysham</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Blevins</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Arakaki</surname>
<given-names>R</given-names>
</string-name> et&#x02009;al. <article-title>Efficacy and safety of dulaglutide added on to pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD&#x02010;1)</article-title>. <source>Diabetes Care</source>
<year>2014</year>; <volume>37</volume>: <fpage>2159</fpage>&#x02013;<lpage>2167</lpage>.<pub-id pub-id-type="pmid">24879836</pub-id></mixed-citation></ref><ref id="dom12534-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="dom12534-cit-0015">
<collab collab-type="authors" id="dom12534-gp-0003">World Medical Association</collab>
. <article-title>World Medical Association declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects</article-title>. <source>JAMA</source>
<year>1997</year>; <volume>277</volume>: <fpage>925</fpage>&#x02013;<lpage>926</lpage>.<pub-id pub-id-type="pmid">9062334</pub-id></mixed-citation></ref><ref id="dom12534-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="dom12534-cit-0016">
<string-name>
<surname>Dmitrienko</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Tamhane</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Wiens</surname>
<given-names>B</given-names>
</string-name>. <article-title>General multistage gatekeeping procedures</article-title>. <source>Biom J</source>
<year>2008</year>; <volume>50</volume>: <fpage>667</fpage>&#x02013;<lpage>677</lpage>.<pub-id pub-id-type="pmid">18932130</pub-id></mixed-citation></ref><ref id="dom12534-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="dom12534-cit-0017">
<string-name>
<surname>Buse</surname>
<given-names>JB</given-names>
</string-name>, <string-name>
<surname>Nauck</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Forst</surname>
<given-names>T</given-names>
</string-name> et&#x02009;al. <article-title>Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION&#x02010;6): a randomised, open&#x02010;label study</article-title>. <source>Lancet</source>
<year>2013</year>; <volume>381</volume>: <fpage>117</fpage>&#x02013;<lpage>124</lpage>.<pub-id pub-id-type="pmid">23141817</pub-id></mixed-citation></ref><ref id="dom12534-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="dom12534-cit-0018">
<string-name>
<surname>Pratley</surname>
<given-names>RE</given-names>
</string-name>, <string-name>
<surname>Nauck</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Barnett</surname>
<given-names>AH</given-names>
</string-name> et&#x02009;al. <article-title>Once&#x02010;weekly albiglutide versus once&#x02010;daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open&#x02010;label, multicentre, non&#x02010;inferiority phase 3 study</article-title>. <source>Lancet Diabetes Endocrinol</source>
<year>2014</year>; <volume>2</volume>: <fpage>289</fpage>&#x02013;<lpage>297</lpage>.<pub-id pub-id-type="pmid">24703047</pub-id></mixed-citation></ref><ref id="dom12534-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="dom12534-cit-0019">
<string-name>
<surname>Kim</surname>
<given-names>YG</given-names>
</string-name>, <string-name>
<surname>Hahn</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Oh</surname>
<given-names>TJ</given-names>
</string-name>, <string-name>
<surname>Park</surname>
<given-names>KS</given-names>
</string-name>, <string-name>
<surname>Cho</surname>
<given-names>YM</given-names>
</string-name>. <article-title>Differences in the HbA1c&#x02010;lowering efficacy of glucagon&#x02010;like peptide&#x02010;1 analogues between Asians and non&#x02010;Asians: a systematic review and meta&#x02010;analysis</article-title>. <source>Diabetes Obes Metab</source>
<year>2014</year>; <volume>16</volume>: <fpage>900</fpage>&#x02013;<lpage>909</lpage>.<pub-id pub-id-type="pmid">24655583</pub-id></mixed-citation></ref><ref id="dom12534-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="dom12534-cit-0020">
<string-name>
<surname>Terauchi</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Satoi</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Takeuchi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Imaoka</surname>
<given-names>T</given-names>
</string-name>. <article-title>Monotherapy with the once&#x02010;weekly GLP&#x02010;1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose&#x02010;dependent effects on glycaemic control in a randomised, double&#x02010;blind, placebo&#x02010;controlled study</article-title>. <source>Endocr J</source>
<year>2014</year>; <volume>61</volume>: <fpage>949</fpage>&#x02013;<lpage>959</lpage>.<pub-id pub-id-type="pmid">25029955</pub-id></mixed-citation></ref><ref id="dom12534-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="dom12534-cit-0021">
<string-name>
<surname>Hirose</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Kawamori</surname>
<given-names>R</given-names>
</string-name>. <article-title>Diabetes in Japan</article-title>. <source>Curr Diab Rep</source>
<year>2005</year>; <volume>5</volume>: <fpage>226</fpage>&#x02013;<lpage>229</lpage>.<pub-id pub-id-type="pmid">15929870</pub-id></mixed-citation></ref><ref id="dom12534-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="dom12534-cit-0022">
<string-name>
<surname>Seino</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Rasmussen</surname>
<given-names>MF</given-names>
</string-name>, <string-name>
<surname>Clauson</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Kaku</surname>
<given-names>K</given-names>
</string-name>. <article-title>The once&#x02010;daily human glucagon&#x02010;like peptide&#x02010;1 analog, liraglutide, improves B&#x02010;cell function in Japanese patients with type 2 diabetes</article-title>. <source>J Diabetes Investig</source>
<year>2012</year>; <volume>3</volume>: <fpage>388</fpage>&#x02013;<lpage>395</lpage>.</mixed-citation></ref><ref id="dom12534-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="dom12534-cit-0023">
<string-name>
<surname>Seino</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Rasmussen</surname>
<given-names>MF</given-names>
</string-name>, <string-name>
<surname>Zdravkovic</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kaku</surname>
<given-names>K</given-names>
</string-name>. <article-title>Dose&#x02010;dependent improvement in glycemia with once&#x02010;daily liraglutide without hypoglycemia or weight gain: a double&#x02010;blind, randomized, controlled trial in Japanese patients with type 2 diabetes</article-title>. <source>Diabetes Res Clin Pract</source>
<year>2008</year>; <volume>81</volume>: <fpage>161</fpage>&#x02013;<lpage>168</lpage>.<pub-id pub-id-type="pmid">18495285</pub-id></mixed-citation></ref><ref id="dom12534-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="dom12534-cit-0024">
<string-name>
<surname>Kaku</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Rasmussen</surname>
<given-names>MF</given-names>
</string-name>, <string-name>
<surname>Clauson</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Seino</surname>
<given-names>Y</given-names>
</string-name>. <article-title>Improved glycaemic control with minimal hypoglycaemia and no weight change with the once&#x02010;daily human glucagon&#x02010;like peptide&#x02010;1 analogue liraglutide as add&#x02010;on to sulphonylurea in Japanese patients with type 2 diabetes</article-title>. <source>Diabetes Obes Metab</source>
<year>2010</year>; <volume>12</volume>: <fpage>341</fpage>&#x02013;<lpage>347</lpage>.<pub-id pub-id-type="pmid">20380655</pub-id></mixed-citation></ref><ref id="dom12534-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="dom12534-cit-0025">
<string-name>
<surname>Robinson</surname>
<given-names>LE</given-names>
</string-name>, <string-name>
<surname>Holt</surname>
<given-names>TA</given-names>
</string-name>, <string-name>
<surname>Rees</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Randeva</surname>
<given-names>HS</given-names>
</string-name>, <string-name>
<surname>O'Hare</surname>
<given-names>JP</given-names>
</string-name>. <article-title>Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta&#x02010;analysis</article-title>. <source>BMJ Open</source>
<year>2013</year>; <volume>3</volume>: <fpage>e001986</fpage>.</mixed-citation></ref><ref id="dom12534-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="dom12534-cit-0026">
<string-name>
<surname>Monami</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Dicembrini</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Nardini</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Fiordelli</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Mannucci</surname>
<given-names>E</given-names>
</string-name>. <article-title>Glucagon&#x02010;like peptide&#x02010;1 receptor agonists and pancreatitis: a meta&#x02010;analysis of randomized clinical trials</article-title>. <source>Diabetes Res Clin Pract</source>
<year>2014</year>; <volume>103</volume>: <fpage>269</fpage>&#x02013;<lpage>275</lpage>.<pub-id pub-id-type="pmid">24485345</pub-id></mixed-citation></ref><ref id="dom12534-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="dom12534-cit-0027">
<string-name>
<surname>Hendarto</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Inoguchi</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Maeda</surname>
<given-names>Y</given-names>
</string-name> et&#x02009;al. <article-title>GLP&#x02010;1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin&#x02010;induced diabetic rats via protein kinase A&#x02010;mediated inhibition of renal NAD(P)H oxidases</article-title>. <source>Metabolism</source>
<year>2012</year>; <volume>61</volume>: <fpage>1422</fpage>&#x02013;<lpage>1434</lpage>.<pub-id pub-id-type="pmid">22554832</pub-id></mixed-citation></ref><ref id="dom12534-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="dom12534-cit-0028">
<string-name>
<surname>Meier</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Gethman</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Gotze</surname>
<given-names>O</given-names>
</string-name> et&#x02009;al. <article-title>Glucagon&#x02010;like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non&#x02010;esterified fatty acids in humans</article-title>. <source>Diabetologia</source>
<year>2006</year>; <volume>49</volume>: <fpage>452</fpage>&#x02013;<lpage>458</lpage>.<pub-id pub-id-type="pmid">16447057</pub-id></mixed-citation></ref><ref id="dom12534-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="dom12534-cit-0029">
<string-name>
<surname>Xiao</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Bandsma</surname>
<given-names>RHJ</given-names>
</string-name>, <string-name>
<surname>Dash</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Szeto</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Lewis</surname>
<given-names>GF</given-names>
</string-name>. <article-title>Exenatide, a glucagon&#x02010;like peptide receptor agonist, acutely inhibits intestinal lipoprotein production in healthy humans</article-title>. <source>Arterioscler Thromb Vasc Biol</source>
<year>2012</year>; <volume>32</volume>: <fpage>1513</fpage>&#x02013;<lpage>1519</lpage>.<pub-id pub-id-type="pmid">22492091</pub-id></mixed-citation></ref><ref id="dom12534-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="dom12534-cit-0030">
<string-name>
<surname>Seino</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Yabe</surname>
<given-names>D</given-names>
</string-name>. <article-title>Glucose&#x02010;dependent insulinotropic polypeptide and glucagon&#x02010;like peptide&#x02010;1: incretin actions beyond the pancreas</article-title>. <source>J Diabetes Investig</source>
<year>2013</year>; <volume>4</volume>: <fpage>108</fpage>&#x02013;<lpage>130</lpage>.</mixed-citation></ref><ref id="dom12534-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="dom12534-cit-0031">
<string-name>
<surname>Ussher</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Drucker</surname>
<given-names>DJ</given-names>
</string-name>. <article-title>Cardiovascular actions of incretin&#x02010;based therapies</article-title>. <source>Circ Res</source>
<year>2014</year>; <volume>114</volume>: <fpage>1788</fpage>&#x02013;<lpage>1803</lpage>.<pub-id pub-id-type="pmid">24855202</pub-id></mixed-citation></ref><ref id="dom12534-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="dom12534-cit-0032">
<string-name>
<surname>Kadowaki</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Namba</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Imaoka</surname>
<given-names>T</given-names>
</string-name> et&#x02009;al. <article-title>Improved glycemic control and reduced body weight with exenatide: a double&#x02010;blind, randomized, phase 3 study in Japanese patients with suboptimally controlled type 2 diabetes over 24 weeks</article-title>. <source>J Diabetes Investig</source>
<year>2011</year>; <volume>2</volume>: <fpage>210</fpage>&#x02013;<lpage>217</lpage>.</mixed-citation></ref><ref id="dom12534-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="dom12534-cit-0033">
<string-name>
<surname>Inagaki</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Atsumi</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Oura</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Saito</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Imaoka</surname>
<given-names>T</given-names>
</string-name>. <article-title>Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug(s): results from a 26&#x02010;week, randomized, open&#x02010;label, parallel&#x02010;group, multicenter, noninferiority study</article-title>. <source>Clin Ther</source>
<year>2012</year>; <volume>34</volume>: <fpage>1892</fpage>&#x02013;<lpage>1908.e1</lpage>.<pub-id pub-id-type="pmid">22884767</pub-id></mixed-citation></ref><ref id="dom12534-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="dom12534-cit-0034">
<string-name>
<surname>Ji</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Onishi</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Ahn</surname>
<given-names>CW</given-names>
</string-name> et&#x02009;al. <article-title>Efficacy and safety of exenatide once&#x02010;weekly vs exenatide twice&#x02010;daily in Asian patients with type 2 diabetes mellitus</article-title>. <source>J Diabetes Investig</source>
<year>2013</year>; <volume>4</volume>: <fpage>53</fpage>&#x02013;<lpage>61</lpage>.</mixed-citation></ref><ref id="dom12534-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="dom12534-cit-0035">
<string-name>
<surname>Riddle</surname>
<given-names>MC</given-names>
</string-name>, <string-name>
<surname>Aronson</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Home</surname>
<given-names>P</given-names>
</string-name> et&#x02009;al. <article-title>Adding once&#x02010;daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24&#x02010;week, randomized, placebo&#x02010;controlled comparison (GetGoal&#x02010;L)</article-title>. <source>Diabetes Care</source>
<year>2013</year>; <volume>36</volume>: <fpage>2489</fpage>&#x02013;<lpage>2496</lpage>.<pub-id pub-id-type="pmid">23628617</pub-id></mixed-citation></ref><ref id="dom12534-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="dom12534-cit-0036">
<string-name>
<surname>Glaesner</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Vick</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Millican</surname>
<given-names>R</given-names>
</string-name> et&#x02009;al. <article-title>Engineering and characterization of the long&#x02010;acting glucagon&#x02010;like peptide&#x02010;1 analogue LY2189265, an Fc fusion protein</article-title>. <source>Diabetes Metab Res Rev</source>
<year>2010</year>; <volume>26</volume>: <fpage>287</fpage>&#x02013;<lpage>296</lpage>.<pub-id pub-id-type="pmid">20503261</pub-id></mixed-citation></ref></ref-list></back></article>